INHIBITORS OF PHOSPHODIESTERASE TYPE-IV Field of the Invention The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors. Background of the Invention It is known that cyclic adenosine-3 ',5 '-monophosphate (cAMP) exhibits an important role of acting as an intracellular secondary messenger. The intracellular hydrolysis of c AMP to adenosine 5 '-monophosphate (AMP) causes a number of inflammatory conditions, which include, but are not limited to, psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, and ulcerative colitis. Cyclic nucleotide phosphodiesterases (PDE), a biochemically and functionally, highly variable superfamily of the enzyme, is the most important factor in the control of cAMP (as well as of cGMP) levels. Eleven distinct families with more than 25 gene products are currently recognized. Although PDE I, PDE II, PDE III, PDE IV, and PDE VII all use cAMP as a substrate, only the PDE IV and PDE VII types are highly selective for hydrolysis of cAMP. Accordingly, inhibitors of PDE, particularly the PDE IV inhibitors, such as rolipram or Ro- 1724, are known as cAMP-enhancers. Immune cells contain PDE rV and PDE III, of which PDE IV is prevalent in human mononuclear cells. Thus, the inhibition of phosphodiesterase type IV has been a target for modulation and, accordingly, for therapeutic intervention in a range of disease processes. The initial observation that xanthine derivatives, theophylline and caffeine inhibit the hydrolysis of cAMP led to the discovery of the required hydrolytic activity in the cyclic nucleotide phosphodiesterase (PDE) enzymes. More recently, distinct classes of PDE have been recognized, and their selective inhibition has led to improved drug therapy. Thus, it was recognized that inhibition of PDE IV could lead to inhibition of inflammatory mediator release and airway smooth muscle relaxation. 3-Aryl-2-isoxazoline derivatives are known as anti-inflammatory agents and isoxazoline compounds are known as inhibitors of TNF release. However, there remains a need for new selective inhibitors of phosphodiesterase (PDE) type IV. Summary of the Invention The present invention provides isoxazoline derivatives, which can be used for the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases, and the processes for the synthesis of these compounds. Pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers or N-oxides of these compounds having the same type of activity are also provided. Pharmaceutical compositions containing the compounds, which may also contain pharmaceutically acceptable carriers or diluents, can be used for the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases. The present invention encompasses a compound having the structure of Formula I, and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers or N-oxides, wherein R1 and R2 together forms an optionally substituted cycloalkyl or heterocyclyl ring wherein one or more optional substituent are oxo, alkyl, alkaryl, alkenyl, alkynyl, heterocyclylalkyl, cycloalkylalkyl, -SO2NRxRy, halogen, -NH2, -(CH2)gC(=O)NRxRy, - NHCO=O)OR6, -NHC(=O)NRxRy , -C(=O)OR3, -NHQ=O)Rx, -SO2R3, cyano, hydroxy, alkoxy, substituted amino, -C(=O)R3; R4 can be hydrogen; alkyl; hydroxy; halogen; carboxy; R7 can be hydrogen; alkyl; R1 is independently hydrogen or alkyl and R2 and R4 forms an optionally substituted 4-12 membered saturated or unsaturated monocyclic or bicyclic ring system fused to ring B having 0-4 heteroatom(s) selected from the group consisting of N, O and S, wherein the substituents is one or more of oxo, alkyl, -C(=O)OR3, -SO2R3, halogen, hydroxy, alkoxy, -NH2 or substituted amino, with the proviso that R2 and R4 together does not form -CH2-O-CH2-O-CH2-; X1 and X2 can be hydrogen, alkyl, cycloalkyl, alkaryl, alkenyl, cycloalkylalkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, -(CH2)gC(=O)NRxRy or - (CH2)glC(=O)OR3 (wherein g can be an integer from 0-3 and g\ can be an integer from 1- 3); X1 and X2 together can optionally form a cyclic ring fused with the ring A shown in Formula I, the ring containing 3-5 carbon atoms within the ring and having 2-3 heteroatoms selected from the group consisting of N, O and S; wherein R3 can be alkyl, cycloalkyl or heterocyclyl; wherein the halogen can be F, Cl, Br, or I; Rx and Ry each independently can be hydrogen, alkyl, C3-C6 alkenyl, C3-C6 alkynyl, carboxy, cycloalkyl, -S(O)mRs, aryl, alkaryl, heteroaryl, heterocyclyl, heteroarylalkyl, and heterocyclylalkyl; m can be an integer between 0-2; R6 can be alkyl, alkenyl, alkynyl, cycloalkyl, alkaryl, heteroarylalkyl or heterocyclylalkyl; wherein R5 can be hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, alkaryl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl; The following definitions apply to terms as used herein: The term "alkyl," unless otherwise specified, refers to a monoradical branched or unbranched saturated hydrocarbon having from 1 to about 20 carbon atoms. This term is exemplified by groups, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t- butyl, n-hexyl, n-decyl, tetradecyl, and the like. The alkyl groups may be further substituted with one or more substituents such as alkenyl, alkynyl, alkoxy, cycloalkyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, arylthio, thiol, alkylthio, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, -S(O)nR5 (wherein n can be 0, 1 or 2 and R5 can be hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, alkaryl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl), heterocyclyl or heteroaryl. Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, aminocarbonyl, hydroxy, alkoxy, halogen, -CF3, amino, substituted amino, cyano, and - S(O)nR5 (wherein n and R5 are the same as defined earlier) or an alkyl group as defined above that is interrupted by 1-5 atoms or groups independently chosen from oxygen, sulfur and -NRa- (where Ra can be hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, or aryl). Unless otherwise constrained by the definition, all substituents may optionally be further substituted by 1-3 substituents chosen from alkyl, carboxy, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)nR5 (wherein n and R5 are the same as defined earlier); or an alkyl group as defined above that has both substituents as defined above and is also interrupted by 1-5 atoms or groups as defined above. The term "alkenyl," unless otherwise specified, refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group preferably having from 2 to 20 carbon atoms with cis or trans geometry. Preferred alkenyl groups include ethenyl or vinyl (CH=CH2), 1 -propylene or allyl (-CH2CH=CH2), or iso-propylene (-C(CH3)=CH2), bicyclo[2.2.1]heptene, and the like. In the event that the alkenyl is attached to a heteroatom, the double bond cannot be alpha to the heteroatom. The alkenyl group may be further substituted with one or more substituents, such as alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, arylthio, thiol, alkylthio, aryl, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, -S(O)nR5 (wherein n and R5 are the same as defined earlier), heterocyclyl or heteroaryl. Unless otherwise constrained by the definition, all substituents may be optionally further substituted by 1-3 substituents, which can be alkyl, carboxy, aminocarbonyl, hydroxy, alkoxy, halogen, -CF3, amino, substituted amino, cyano, or -S(O)nR5 (wherein R5 and n are the same as defined earlier). The term "alkynyl," unless otherwise specified, refers to a monoradical of an unsaturated hydrocarbon, preferably having from 2 to 20 carbon atoms. Preferred alkynyl groups include ethynyl, (-C=CH), or propargyl (or propynyl, -CH2C=CH), and the like. In the event that the alkynyl is attached to a heteroatom, the triple bond cannot be alpha to the heteroatom. The alkynyl group may be further substituted with one or more substituents, such as alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, arylthio, thiol, alkylthio, aryl, aryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, or -S(O)nR5 (wherein R5 is the same as defined earlier). Unless otherwise constrained by the definition, all substituents maybe optionally further substituted by 1-3 substituents, which can be alkyl, carboxy, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano or - S(O)nR5 (wherein R5 and n are the same as defined earlier). The term "cycloalkyl," unless otherwise specified, refers to saturated or unsaturated cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings, which contains an optional olefinic bond. Such cycloalkyl groups include, by way of example, single ring structures, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, cyclopropylene, cyclobutylene and the like, or multiple ring structures, such as adamantanyl, and bicyclo [2.2.1]heptane, or cyclic alkyl groups to which is fused an aryl group, for example, indane and the like. The cycloalkyl may be further substituted with one or more substituents such as alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, arylthio, thiol, alkylthio, aryl, aryloxy, alkaryloxy, aminosulfonyl, aminocarbonylamino, hydroxyamino, alkoxyamino, nitro, -S(O)nR5 (wherein R5 is the same as defined earlier), heteroaryl or heterocyclyl. Unless otherwise constrained by the definition, all substituents may be optionally further substituted by 1-3 substituents, which can be alkyl, carboxy, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, -NH2, substituted amino, cyano, or -S(O)nR5 (wherein R5 and n are the same as defined earlier). The term "alkoxy" denotes the group O-alkyl, wherein alkyl is the same as defined above. The term "alkaryl" refers to alkyl-aryl linked through alkyl portion (wherein alkyl is the same as defined earlier) and the alkyl portion contains carbon atoms from 1-6 and aryl is same as defined below. The term "aryl," unless otherwise specified, refers to phenyl or naphthyl ring, and the like, optionally substituted with 1 to 3 substituents selected from the group consisting of halogen (such as F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, -S(O)nR5 (wherein R5 is the same as defined earlier), cyano, nitro, carboxy, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl, acyl and (CH2)o-3C(=O)NRxRy (wherein Rx and Ry are same as defined earlier). The term "carboxy," unless otherwise specified, refers to -C(=O)O-R6, wherein R6 can be, for example, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, alkaryl, heteroarylalkyl or heterocyclylalkyl. The term "heteroaryl," unless otherwise specified, refers to an aromatic ring structure containing 5 or 6 carbon atoms, or a bicyclic aromatic group having 8 to 10 carbon atoms, with one or more heteroatom(s) independently selected from the group consisting of N, O and S, optionally substituted with 1 to 3 substituent(s), such as halogen (F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, -S(O)nR5 (wherein n and R5 are the same as defined earlier), alkoxy, alkaryl, cyano, nitro, acyl or C(=O)NRxRy (wherein Rx and Ry are the same as defined earlier). Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidinyl, pyrrolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, triazinyl, furanyl, benzofuranyl, indolyl, benzothiazolyl, benzoxazolyl, and the like, including analogous oxygen, sulphur, and mixed hetero atom containing groups. The term 'heterocyclyl," unless otherwise specified, refers to a saturated or unsaturated monocyclic or polycyclic ring having 5 to 10 atoms, in which 1 to 3 carbon atoms in a ring are replaced by heteroatoms selected from the group consisting of O, S and N, and optionally are benzofused or fused heteroaryl of 5-6 ring members and/or optionally are substituted, wherein the substituents can be halogen (F, Cl, Br, I), hydroxy, alkyl, alkenyl, alkynyl, hydroxyalkyl, cycloalkyl, carboxy, aryl, alkoxy, alkaryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, oxo, alkoxyalkyl or -S(O)nR5 (wherein n and R5 are the same as defined earlier), cyano, nitro, -NH2 substituted amino, acyl or -C(=0)NRxRy (wherein Rx and Ry are the same as defined earlier). Examples of heterocyclyl groups include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, azabicyclohexane dihydropyridinyl, piperidinyl, isoxazoline, piperazinyl, dihydrobenzofuryl, isoindole-dione, dihydroindolyl, and the like. "Heteroarylalkyl," unless otherwise specified, refers to an alkyl-heteroaryl group, wherein the alkyl and heteroaryl portions are the same as defined earlier. "Heterocyclylalkyl," unless otherwise specified, refers to an alkyl-heterocyclyl group, wherein the alkyl and heterocyclyl portions of the group are the same as defined earlier. The term "acyl" as defined herein refers to -C(=O)R", wherein R" is the same as defined earlier. The term "substituted amino," unless otherwise specified, refers to a group -N(Rk)2 wherein each Rk can be hydrogen [provided that both Rk groups are not hydrogen (defined as "-NH2")], alkyl, alkenyl, alkynyl, alkaryl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, acyl, S(O)mR5 (wherein m and R5 is the same as defined above), -C(=O)NRxRy, -C(=O)ORX (wherein Rx and Ry are the same as defined earlier) or -NHC(=O)NRyRx (wherein Ry and Rx are the same as defined earlier). Unless otherwise constrained by the definition, all substituents optionally may be further substituted by 1-3 substituents, which can be alkyl, alkaryl, cycloalkyl, aryl, heteroaryl, heterocyclyl, carboxy, hydroxy, alkoxy, halogen, -CF3, cyano, -C(=O)NRxRy, -0(C=O)NRxRy (wherein Rx and Ry are the same as defined earlier) and -OC(=O)NRxRy or -S(O)mR5 (where R5 is the same as defined above and m is 0, 1 or 2). The compounds of the present invention can be used for treating AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases. Accordingly, the present invention encompasses a method of treating AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis or other inflammatory diseases, which comprises administering to a patient in need thereof a therapeutically effective amount of an isoxazoline derivative compound of the present invention, and particularly an isoxazoline derivative compound of the present invention together a pharmaceutically acceptable carrier, excipient or diluent. Li accordance with yet another aspect, there are provided processes for the preparation of the compounds as described herein. The compounds of the present invention may be prepared by techniques well known in the art. hi addition, the compounds of the present invention may be prepared following a reaction sequence as depicted below. The compounds of this invention contain one or more asymmetric carbon atoms and thus occur as racemic mixtures, enantiomers and diastereomers. These compounds also exist as conformers/rotamers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereo genie carbon may be of the R ov S configuration. Although the specific compounds exemplified in this application may be depicted in a particular stereochemical configuration, compounds having either the opposite stereochemistry at any given chiral center or mixtures thereof are envisioned as part of the invention. Detailed Description of the Invention The compounds of the present invention may be prepared by techniques well known in the organic synthesis and familiar to a practitioner skilled in art of this invention, hi addition, the process described herein may prepare the compounds of the present invention, however that may not be the only means by which the compounds described may be synthesised. Further, the various synthetic steps described herein may be performed in an alternate sequence in order to give the desired compounds. Scheme I The compounds of Formulae VII, IX, XI, XIII and XV can be prepared by following the reaction sequence as depicted for example in Scheme I. Thus, a compound of Formula I (wherein n can be 1, 2 or 3) can be N-protected to give a compound of Formula II (wherein P1 can be -C(=O)OC(CH3)3, -C(=O)OC(CH3)2CHBr2 or - C(=O)OC(CH3)2CCl3), which can be oxidized to give a compound of Formula III, which can undergo methylenation to give a compound of Formula IV, which can be reacted with a compound of Formula V (which was prepared following the procedure as described in U.S. Patent Application No. 10/930,569 wherein R2 is alkyl optionally substituted with halogen (for example, trifluoromethyl) or alkaryl (for example, benzyl) and Rzl can be cycloalkylalkyl, alkaryl, cycloalkyl or alkyl optionally substituted with halogen) to give a compound of Formula VI, which can be deprotected to give a compound of Formula VII, which can be reacted with Path a: a compound of Formula VIII (wherein Y is oxygen or sulphur and Rx is the same as defined earlier) to give a compound of Formula IX; Path b: a compound of Formula X (wherein A' is -NRxRy or alkyl where Rx and Ry are the same as defined earlier) to give a compound of Formula XI; Path c: a compound of Formula XII (wherein A" is cycloalkyl, heterocyclyl or alkyl) to give a compound of Formula XIII; or Path d: a compound of Formula XIV (wherein hal is Br, Cl or I and A'" is heterocyclylalkyl, cycloalkylalkyl, alkaryl or alkyl optionally substituted with -CONRxRy wherein Rx and Ry are the same as defined earlier). The N-protection of a compound of Formula I to give a compound of Formula II [wherein P can be -C(=O)OC(CH3)3] can be carried out in an organic solvent, such as, for example, dichloromethane, dichloroethane, chloroform or carbon tetrachloride, in the presence of a base, such as, for example triethylamine, diisopropylethylamine, N- methylmorpholine or pyridine. The N-protection of a compound of Formula I to give a compound of Formula II [when P can be -C(=O)OC(CH3)2CHBr2 or -C(=O)OC(CH3)2CC13] can be carried out following procedures described in Theodora W. Greene and Peter G.M. Wuts, "Protecting Groups In Organic Synthesis," 3rd edition, John Wiley and Sons, New York 1999. The oxidation of a compound of Formula II to give a compound of Formula III can be carried out using an oxidizing agent, such as, for example, pyridinium chlorochromate, manganese dioxide, potassium permanganate or Jones reagent (CrO3/H2SO4). The methylenation of a compound of Formula III to give a compound of Formula TV can be carried out in an organic solvent, such as, for example, tetrahydrofuran, dimethylformarmde, dioxane or diethylether, in the presence of a Wittig salt for example, triphenylmethylphosphonium iodide or triphenylmethylphosphonium bromide. Alternatively, the methylenation of a compound of Formula III to give a compound of Formula IV can be carried out using Zn/CH2Br2/ TiCl4 in an organic solvent, such as, for example, tetrahydrofuran, dimethylformamide, dioxane or diethylether. The reaction of a compound of Formula IV with a compound of Formula V to give a compound of Formula VI can be carried out in an organic solvent, such as, for example, dichloromethane, chloroform, carbon tetrachloride or dichloroethane, tetrahydrofuran with oxidants such as, for example, sodium hypochlorite, N-chlorosuccinimide or tert- butoxychloride in the presence of an optional base, such as, for example, pyridine, butyl lithium, N-rnethylmorpholine, diisopropylethylamine or triethylamine. The deprotection of a compound of Formula VI (wherein P can be - C(=O)OC(CH3)3) to give a compound of Formula VII can be carried out in an organic solvent, such as, for example, methanol, ethanol, propanol or isopropylalcohol, in the presence of an alcoholic acid solution, such as, for example, ethanolic hydrochloric acid or methanolic hydrochloric acid. The deprotection of a compound of Formula VI (wherein P can be -C(=O)OC(CH3)2CHBr2) can be carried out in an organic solvent, such as, for example, ethanol, methanol, propanol or isopropylalcohol in the presence of hydrobromic acid or hydrochloric acid). The deprotection of a compound of Formula VI (wherein P can be -C(=O)OC(CH3)2CC13) can be carried out by a supernucleophile, such as, for example, lithium cobalt (I) phthalocyanine, zinc and acetic acid or cobalt phthalocyanine. The compound of Formula VII can be reacted with a compound of Formula VIII (path a) to give a compound of Formula IX in an organic solvent, such as, for example, dichloroethane, dichloromethane, chloroform or carbon tetrachloride in the presence of a base such as, for example, triethylamine, diisopropylethylamine, N-methylmorpholine or pyridine. The compound of Formula VII can be reacted with a compound of Formula X (path b) to give a compound of Formula XI in an organic solvent, such as, for example, dichloroethane, dichloromethane, chloroform or carbon tetrachloride in the presence of a base such as, for example, triethylamine, diisopropylethylamine, N-methylmorpholine or pyridine. The compound of Formula VII can be reacted with a compound of Formula XII (path c) to give a compound of Formula XIII in an organic solvent, such as, for example, dimethylformamide, tetrahydrofuran, diethylether or dioxane in the presence of a base such as, for example, N-methylmorpholine, triethylamine, diisopropylethylamine or pyridine. The compound of Formula VII can be reacted with a compound of Formula XIV (path d) to give a compound of Formula XV in an organic solvent, such as, for example, dimethylformamide, tetrahydrofuran, diethylether or dioxane in the presence of a base such as, for example, potassium carbonate, sodium carbonate or lithium carbonate. Some representative compounds which can be prepared following Scheme I include: rert-butyl 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.5]dec-2-ene- 7-carboxylate (Compound No. 21), Hydrochloride salt of 3-[3-(cyclopentyloxy)-4-methoxyphenyl]- 1 -oxa-2,7- diazaspiro[4.5]dec-2-ene (Compound No. 25), Some representative compounds which can be prepared following Scheme I, path a include: 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-N-(4-fluorophenyl)-l-oxa-2,7- diazaspiro[4.4]non-2-ene-7-carboxamide (Compound No. 2), ΛT-butyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-ene-7- carboxamide (Compound No. 5), iV-butyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene-8- carboxamide (Compound No. 9), iV-benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-ene-7- carboxamide (Compound No. 19), iV-Benzyl-3-[3-(cyclopentyloxy)-4-inethoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene-8- carboxamide (Compound No. 32), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]- 1 -oxa-2,8-diazaspiro[4.5]dec-2-ene-8- carboxamide (Compound No. 143), 7V-5utyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.5]dec-2-ene-7- carboxamide (Compound No. 144). Some representative compounds which can be prepared following Scheme I, path b include: 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-iV,iV-dimethyl-l-oxa-2,7-diazaspiro[4.4]non-2- ene-7-sulfonamide (Compound No. 4), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-8-(methylsulfonyl)-l-oxa-2,8- diazaspiro[4.5]dec-2-ene (Compound No. 10), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-7-(methylsulfonyl)-l-oxa-2,7- diazaspiro[4.5]dec-2-ene (Compound No. 145). Some representative compounds which can be prepared following Scheme I, path c include: 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-7-(tetrahydroruran-3-ylcarbonyl)-l-oxa-2,7- diazaspiro[4.4]non-2-ene (Compound No. 3), Hydrochloride salt of 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-8-prolyl-l-oxa-2,8- diazaspiro[4.5]dec-2-ene (Compound No. 7), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-7-(cyclopropylcarbonyl)-l-oxa-2,7- diazaspiro[4.4]non-2-ene (Compound No. 18), 7-acetyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-ene (Compound No. 20), 8-Acetyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 48), 8-(Cyclopentylcarbonyl)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8- diazaspiro[4.5]dec-2-ene (Compound No. 49), 7-(Cyclopentylcarbonyl)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7- diazaspiro[4.5]dec-2-ene (Compound No. 141), 7-Acetyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.5]dec-2-ene (Compound No. 155). Some representative compounds which can be prepared following Scheme I, path d include: 2-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-en-7- yl}acetamide (Compound No. 6), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-(2-morpholin-4-yl-ethyl)-l-oxa-2,8- diazaspiro[4.5]dec-2-ene (Compound No. 8), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-7-isopropyl- 1 -oxa-2,7-diazaspiro[4.4]non-2-ene (Compound No. 17), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-(cyclopropylmethyl)-l-oxa-2,8- diazaspiro[4.5]dec-2-ene (Compound No. 31), 8-Benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 38), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-(2-piperidin- 1 -ylethyl)- 1 -oxa-2,8- diazaspiro[4.5]dec-2-ene (Compound No. 50), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-ethyl-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 54). Compounds of Formulae XXIV, XXV, XXVI and XXVII can be prepared, for example, by following a reaction sequence of Scheme II. Thus, the compound of Formula XVI can be reacted with a compound of Formula XVII (wherein B' can be alkaryl) to give a compound of Formula XVIII, which can be reacted with hydroxyl amine hydrochloride to give a compound of Formula XIX, which can be reacted with a compound of Formula XX (wherein P can be alkyl or alkaryl) to give a compound of Formula XXI, which can undergo hydrolysis to give a compound of Formula XXII, which can undergo reduction to give a compound of Formula XXIII, which can undergo ring cyclisation to give a compound of Formula XXW which can undergo deprotection to give a compound of Formula XXV, which can be reacted with Path a: a compound of Formula hal(CH2)vhal [wherein hal is (Br, Cl or I) and v is an integer from 1-4] to give a compound of Formula XXVI; or Path b: a compound of Formula B" hal (wherein B" is alkyl) and hal is the same as defined above) to give a compound of Formula XXVII. The reaction of compound of Formula XVI with a compound of Formula XVII to give a compound of Formula XVIII can be carried out in an organic solvent, such as, for example, dimethylformamide, tetrahydrofuran, diethylether or dioxane, in the presence of base, such as, for example, potassium carbonate, sodium carbonate or sodium bicarbonate. The reaction of a compound of Formula XVIII with hydroxylamine hydrochloride to give a compound of Formula XIX can be carried out in an organic solvent, such as, for example, ethanol, methanol, propanol or isopropylalcohol. The compound of Formula XIX can be reacted with a compound of Formula XX to give a compound of Formula XXI in an organic solvent, such as, for example, dichloromethane, chloroform, carbon tetrachloride or dichloroethane with oxidants such as, for example, sodium hypochlorite, N-chlorosuccinimide or tert-butoxychloride in the presence of an optional base, such as, for example, pyridine, butyl lithium, N- methylmorpholine, diisopropylethylamine or triethylamine The hydrolysis of a compound of Formula XXI to give a compound of Formula XXII can be carried out in a solvent system, such as, for example, tetrahydrofuran, methanol, dioxane or ethanol, in water in the presence of base, such as, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide. The compound of Formula XXII can undergo reduction to give a compound of Formula XXIII in an organic solvent, such as, for example, tetrahydrofuran, dimethylformamide, dioxane or diethyl ether, with reducing agent, such as, for example, sodium borohydride or lithium borohydride or lithium aluminium hydride. The compound of Formula XXIII can undergo ring cyclisation to give a compound of Formula XXIV in an organic solvent, such as, for example, tetrahydrofuran, dimethylformamide, dioxane or diethyl ether in the presence of a redox couple. The oxidizing part of the redox couple is selected from the group diisopropylazodicarboxylate (DIAD), diethylazodicarboxylate (DEAD), N,N,N',N'-tetramethylazodicarboxylate (TMAD), l,l'-(azodicarbonyl) dipiperidine (ADDP), cyanomethylenetributylphosphorane (CMBP), 4,7-dimethyl-3,5,7-hexahydro-l,2,4,7-tetrazocin-3,8-dione (DHTD) or N,N,N',N,'-tetraisoρropylazodicarboxamide (TIPA). The reduction part of the redox couple is phosphine such as, for example, trialkylphosphine (such as tributylphosphine), triarylphosphine (such as triphenylphosphine), tricycloalkylphosphine (such as triscyclohexylphosphine) or tetraheteroarylphosphine. The phosphine reagents with a combination of aryl, alkyl or heteroaryl substituents may also be used (such as diphenylpyridylphosphine) . The compound of Formula XXIV can be deprotected to give a compound of Formula XXV in an organic solvent, such as, for example, methanol, ethanol, propanol or isopropylalcohol with a deprotecting agent, such as, for example, palladium on carbon or palladium on carbon with ammonium formate. The compound of Formula XXV (path a) can be reacted with a compound of Formula hal(CH2)vhal to give a compound of Formula XXVI in an organic solvent such as, for example, dimethylformamide, tetrahydrofuran, diethyl ether or dioxane in the presence of a base such as, for example, potassium carbonate, sodium carbonate or lithium carbonate. The compound of Formula XXV (path b) can be reacted with a compound of Formula B'lial to give a compound of Formula XXVII in an organic solvent such as, for example, dimethylformamide, tetrahydrofuran, diethylether or dioxane in the presence of a base such as, for example, potassium carbonate, sodium carbonate or lithium carbonate. Some representative compounds which may be prepared following- Scheme II include: 3-[3,4-Bis(benzyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 33), 4-(l,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl)benzene-l,2-diol (Compound No. 34). Some representative compounds which may be prepared following Scheme II, path a include: 3-(2,3-Dihydro-l,4-benzodioxin-6-yl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 51). Some representative compounds prepared following Scheme II, path b include: 3-[3,4-bis(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 12), 3-(3,4-diisopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 13), 3-[3,4-bis(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 27), 3-[3,4-Bis(cyclopropylmemoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 28), The compounds of Formula XXX can be prepared by following the procedure as depicted in scheme III. Thus a compound of Formula XXVIII (wherein Rz1 is the same as defined earlier) undergoes demethylation to give a compound of Formula XXIX, which was reacted, with a compound of Formula C'-hal (wherein C is heterocyclylalkyl, cycloalkylalkyl, cycloalkyl or C2-10 alkyl optionally substituted with halogen) to give a compound of Formula XXX. The demethylation of a compound of Formula XXVIII to give a compound of Formula XXIX can be carried out with reducing agent such as, for example, sodium ethane thiolate, sodium decane thiolate, sodium dodecane thiolate, sodium thiocresolate in the presence of solvent for example N,N-dimethylacetamide, hexamethyl phosphoramide or dimethylformamide. The reaction of a compound of Formula XXIX with a compound of Formula C'- hal can be carried out in an organic solvent such as, for example, dimethylformamide, tetrahydrofuran, diethyl ether or dioxane in the presence of a base such as, for example, potassium carbonate, sodium carbonate or lithium carbonate. Some representative compounds which may be prepared following Scheme III include: 2-(Cyclopentyloxy)-4-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol (Compound No. 62), 3-(4-Butoxy-3-isobutoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 63), 3-(3-Isobutoxy-4-propoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 64), 3-[3-Butoxy-4-(cycloρropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 65), 3-(3-Butoxy-4-ethoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 66), 3-[3-Butoxy-4-(cyclohexyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 67), 3-[3-(Cyclohexylmethoxy)-4-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 68), 3-[3-(Cyclohexylmethoxy)-4-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 69), 3-[4-Butoxy-3-(cyclohexylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 70), 3-(4-Isobutoxy-3-isopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 71), 3-(4-Butoxy-3-isopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 72), 3-[4-(Cyclohexylmethoxy)-3-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 73), 3-[3-Isopropoxy-4-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 74), 3-[3-(Cyclopropylmethoxy)-4-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 75), 3-[3-(Cyclopropylmethoxy)-4-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2- azaspiro[4.4]non-2-ene (Compound No. 76), 3-[4-Butoxy-3-(Gyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 77), 3-[3-(Cyclopropylmethoxy)-4-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 78), 3-(3-Isobutoxy-4-isopropoxyphenyl)- 1 ,7-dioxa-2-azasρiro[4.4]non-2-ene (Compound No. 79), 3 - [4-(Cyclopropylmethoxy)-3 -isobutoxyphenyl] - 1 , 7-dioxa-2-azaspiro [4.4]non-2-ene (Compound No. 80), 3-[4-(cyclohexyloxy)-3-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 81) 3-[4-(Cyclohexylmethoxy)-3-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- ene (Compound No. 82), 3-[4-(Cyclopropylmethoxy)-3-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- ene (Compound No. 83), 3-[3-(Cyclopentyloxy)-4-isobutoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 84), 3-[3-(Cyclopentyloxy)-4-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 85), 3-[3-(Cyclopropylmethoxy)-4-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 86), 3-[4-(Cyclopentyloxy)-3-isobutoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 87), 3-[3-Isopropoxy-4-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 88), 3-(4-Ethoxy-3-isobutoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 89) 3-[3-(Cyclopentyloxy)-4-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 90), 3-[4-Butoxy-3-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 91), 3 -[3-(Cyclopentyloxy)-4-isopropoxyphenyl] - 1 ,7-dioxa-2-azaspiro [4.4]non-2-ene (Compound No. 92), 3-[3-(Cyclopentyloxy)-4-(cycloheptyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 93), 3-[3-(Cyclopentyloxy)-4-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non- 2-ene (Compound No. 94), 3-[4-(Cyclohexylmethoxy)-3-isobutoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 95), 3-[4-(Cyclohexylmethoxy)-3-(cyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non- 2-ene (Compound No. 96), 3-[3-(Cyclopropylmethoxy)-4-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 97), 3-[4-(Cyclopentyloxy)-3-(cyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- ene (Compound No. 98), 3-[4-(Cyclopropylmethoxy)-3-isoproρoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 99), 3-[4-(Cyclopentyloxy)-3-isopropoxyphenyl]-l,7-dioxa-2-azasρiro[4.4]non-2-ene (Compound No. 100), 3-(3-Isopropoxy-4-propoxyphenyl)-l ,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 101), 3-(4-Ethoxy-3-isopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 102), 3-[3-Butoxy-4-(2-moφholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 103), 3-[3-Butoxy-4-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 104), 3-(3-Butoxy-4-propoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 105), 3-(3-Butoxy-4-isopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 106), 3-[3-(Cyclohexylmethoxy)-4-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 107), 3-[3-(Cyclohexylmethoxy)-4-isobutoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 108), 3-[3-(Cyclohexylmethoxy)-4-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- ene (Compound No. 109), 3-[3-(Cyclohexylmethoxy)-4-(cyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non- 2-ene (Compound No. 110), 3-[4-(Cyclohexylmethoxy)-3-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. I l l), 3-[4-(Cyclopropylmethoxy)-3-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 112), 3-[4-(Cyclopentyloxy)-3-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 113), 3-[4-(3-Isobutoxy)-3-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 114), 3-[3-(Cycloheptyloxy)-4-(cyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- ene (Compound No . 115), 3-[3-(Cycloheptyloxy)-4-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 116), 3-[4-Butoxy-3-(cycloheptyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 117), 3-[3-(Cycloheptyloxy)-4-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 118), 3-[3-(Cycloheptyloxy)-4-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 119), 3-(3-Ethoxy-4-propoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 120), 3-[4-(Cycloheptyloxy)-3-etlioxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 121), 3-[4-(Cyclopropylmethoxy)-3-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 122), 3-[4-(Cyclohexylmethoxy)-3-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 123), 3-(3-Butoxy-4-isobutoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 125), 3-(3-Ethoxy-4-isopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 126), 3-[4-(Cyclopentyloxy)-3-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 127), 3-(4-Butoxy-3-ethoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 128), 3-(3-Ethoxy-4-isobutoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 129), 3 -[3-(Cycloheptyloxy)-4-isobutoxyphenyl] - 1 ,7-dioxa-2-azaspiro [4.4]non-2-ene (Compound No. 130), 3-[3-(Cycloheptyloxy)-4-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 131), 3 -[3-(Cycloheptyloxy)-4-ethoxyphenyl] - 1 ,7-dioxa-2-azaspiro [4.4]non-2-ene (Compound No. 132), 3-(4-Butoxy-3-ρropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 133), 3-(4-Ethoxy-3-ρropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 134), 3-[4-(Morpholin-4-ylethoxy)-3-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 135), 3-(4-Isopropoxy-3-propoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 136), 3-[4-(Difluoromethoxy)-3-(2,3-dihydro-lH-inden-2-yloxy)phenyl]-l,7-dioxa-2- azaspiro[4.4]non-2-ene (Compound No. 151), 3-[4-(Cyclopentyloxy)-3-(2,3-dihydro-lH-inden-2-yloxy)phenyl]-l,7-dioxa-2- azaspiro[4.4]non-2-ene (Compound No. 152), 3-[4-Butoxy-3-(2,3-dihydro-lH-inden-2-yloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- ene (Compound No. 153), 3-[3-(2,3-Dihydro-lHr-inden-2-yloxy)-4-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- ene (Compound No. 157), 3-[3 -(2,3 -Dihydro- lH-inden-2-yloxy)-4-propoxyphenyl] - 1 ,7-dioxa-2-azaspiro [4.4]non-2- ene (Compound No. 158), 3-[4-(Cyclopropylmethoxy)-3-(2,3-dihydro-lH-inden-2-yloxy)phenyl]-l,7-dioxa-2- azaspiro[4.4]non-2-ene (Compound No. 159), 3-[3-(2,3-Dihydro-lH-inden-2-yloxy)-4-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non- 2-ene (Compound No. 160), 2-(2,3-Dihydro-lH-inden-2-yloxy)-4-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)plienol (Compound No. 161), Scheme IV Formula XXXI Compounds of Formulae XXXIII and XXXV can be prepared, for example, by following the reaction sequence as depicted, for example, in Scheme IV. Thus, the compound of Formula XXXI (prepared following the procedure reported in U.S. Patent Application No. 10/930,569 wherein Rz is the same as defined above) can be reacted with a compound of Formula XXXII [wherein Rw can be heteroarylalkyl, alkenyl or alkyl optionally substituted with cyano, carboxy or halogen and hal can be Br, Cl or I) to give a compound of Formula XXXIII, which can be reacted with a compound of formula XXXIV (wherein D' is cycloalkyl or hydrogen) to give a compound of Formula XXXV. The reaction of a compound of Formula XXXI with a compound of Formula XXXII to give a compound of Formula XXXIII can be carried out in an organic solvent, such as, for example, dimethylformamide, tetrahydrofuran, diethylether or dioxane, in the presence of base, such as, for example, potassium carbonate, sodium carbonate or sodium bicarbonate. The compound of Formula XXXIII can be reacted with a compound of Formula XXXIV to give a compound of Formula XXXV. Particular compounds which can be formed following the procedure shown in Scheme VII include: 3-[3-(Difluoromethoxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 40), 3-[3-(Allyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 60), 3-[3-(2-Chloroethoxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 61), 3-[4-Methoxy-3-(pyridin-3-ylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 146), 3-[4-Methoxy-3-(pyridin-2-ylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 156), JV-cyclopropyl-2-[5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2- methoxyphenoxyjacetamide (Compound No. 162), 2-[5-(l,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetamide (Compound No. 164), Ethyl [5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetate (Compound No. 165), [5-(l,7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetonitrile (Compound No. 166), The compounds of Formulae XXXVII, XXXVIII and XXXIX can be prepared by following the procedure as depicted in Scheme V. Thus a compound of Formula XXXVI (prepared following the procedure disclosed in U.S. Patent Application No. 10/930,569 wherein Rz and RzI are the same as defined earlier) can be reacted with Path a: a compound of Formula VIII (wherein Y and Rx are the same as defined earlier) to give a compound of Formula XXXVII; Path b: a compound of Formula XII (wherein A" is the same as defined earlier) to give a compound of Formula XXXVIII; or Path c: a compound of Formula X (wherein A' is the same as defined earlier) to give a compound of Formula XXXIX. The compound of Formula XXXVI can be reacted with a compound of Formula VIII (path a) to give a compound of Formula XXXVII in an organic solvent, such as, for example, dichloroethane, dichloromethane, chloroform or carbon tetrachloride in the presence of a base such as, for example, triethylamine, diisopropylethylamine, N- methylmorpholine or pyridine. The compound of Formula XXXVI can be reacted with a compound of Formula XII (path b) to give a compound of Formula XXXVIII in an organic solvent, such as, for example, dimethylformamide, tetrahydrofuran, diethylether or dioxane in the presence of a base such as, for example, N-methylmorpholine, triethylamine, diisopropylethylamine or pyridine. The compound of Formula XXXVI can be reacted with a compound of Formula X (path c) to give a compound of Formula XXXIX in an organic solvent, such as, for example, dichloroethane, dichloromethane, chloroform or carbon tetrachloride in the presence of a base such as, for example, triethylamine, diisopropylethylamine, N- methylmorpholine or pyridine. Some representative compounds which may be prepared following Scheme V, path a include: iV-butyl-iV-{3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8- yl}urea (Compound No. 22), N-{3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-yl}-Λ/I-(2- methoxyphenyl)urea (Compound No. 23), lert-butyl [({3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8- yl}amino)carbonyl]carbamate (Compound No. 46), Some representative compounds which may be prepared following Scheme V, path b include: N-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8- yljcyclopentanecarboxamide (Compound No. 47), N-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-yl}-2- fluorobenzamide (Compound No. 138), iV-{3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8- yljbenzamide (Compound No. 139). Some representative compounds which may be prepared following Scheme V, path c include: N-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8- yl}methanesulfonamide (Compound No. 58), Scheme Vl The compounds of Formulae XLIII, XLIV, XLV, XLVI, XLVII, XLVIII, XLIX, L, LI and LIV can be prepared, for example, by following the procedure as described, for example, in Scheme VI. Thus a compound of Formula XL (wherein X1 and X2 are the same as defined earlier) can be reacted with a compound of Formula XLI, wherein a. Rh and R; may together join to form a cycloalkyl or heterocyclyl ring optionally substituted with alkaryl or oxo; Rj is hydrogen or -COOalkyl and Rk is hydrogen, b. Rh is hydrogen or -CH2OH; Rj is -(CH2)1-2OH; R,- is hydrogen or -(CH2)1-2OH and Rk is hydrogen, c. Ri and Rj together joins to form cycloalkyl or heterocyclyl ring; Rh and Rk are hydrogen; to give a compound of Formula XLII, which can undergo hydrolysis (when Rj is - COOalkyl) to give a compound of Formula XLIII, path a: the compound of Formula XLII undergoes dehydration (when Ri = Rj = -(CH2)1-2OH) to give a compound of Formula XLIV; Path b: the compound of Formula XLII undergoes oxidation (when Rh is -CH2OH and Rj is -(CH2)1-2OH) to give a compound of Formula XLV, which undergoes reduction to give a compound of Formula XLVI; Path c: the compound of Formula XLII undergoes deprotection (R; and Rj together joins to form NPi wherein * represents a point of attachment and P1 represents - C(=O)OC(CH3)3, -C(=O)OC(CH3)2CHBr2 or -C(=O)OC(CH3)2CC13) to give a compound of Formula XLVII, [Path cl : which can be reacted with a compound of Foπnula XII (wherein A" is the same as defined earlier) to give a compound of Formula XLVIII]; or [Path c2: which can be reacted with a compound of Formula X (wherein A' is the same as defined earlier) to give a compound of Formula XLIX]; Path d: the compound of Formula XLII undergoes reduction (when Rh and Rj together -o joins to form ° wherein * represents a point of attachment) to give a compound of Formula L; Path e: the compound of Formula XLII can be reacted with a compound of Formula LI (wherein Rx is the same as defined earlier) to give a compound of Formula LII, which can be reacted with a compound of Formula X to give a compound of formula LIII, which undergoes cyclisation to give a compound of Formula LIV; or Path/: the compound of Formula XLII can be reacted with hydrazine hydrochloride to give a compound of Foπnula LIVa. The reaction of a compound of Formula XL with a compound of Formula XLI to give a compound of Formula XLII can be carried out in an organic solvent, such as, for example, dichloromethane, chloroform, carbon tetrachloride, dichloromethane or tetrahydrofuran, with oxidants such as, for example, sodium hypochlorite, N- chlorosuccinimide or tert-butoxychloride, in the presence of an optional base, such as, for example, pyridine, butyl lithium, N-methylmorpholine, diisopropylethylamine or triethylamine. The compound of Formula XLII can undergo hydrolysis (when Rj is -COOalkyl) to give a compound of Formula XLIII in the presence of a basic hydrolyzing agent, such as, for example, sodium hydroxide, lithium hydroxide, potassium hydroxide, and a mixture thereof. The compound of Formula XLII can undergo dehydration (when Rj = Rj = -(CH2)1-2OH) at temperature ranging from about 100-1500C to give a compound of Formula XLIV with dehydrating agents, such as, for example, acetic anhydride, glacial acetic acid, calcium oxide or sulphuric acid. The compound of Formula XLII can undergo oxidation (path b, when Rh is - CH2OH and R; is -(CH2)1-2OH) to give a compound of Formula XLV in an organic solvent, such as, for example, dichloromethane, dichloroethane, chloroform or carbon tetrachloride, in the presence of a base for example, pyridine, triethylamine, N- methylmorpholine or diisopropylethylamine with oxidizing agents, such as, for example, chromic anhydride, sodium dichromate, potassium permanganate or potassium dichromate, pyridium chlorochromate or pyridinium dichromate The compound of Formula XLV can undergo reduction to give a compound of Formula LXVI in an organic solvent, such as, for example, toluene, benzene or xylene, with reducing agent diisobutylaluminium hydride, sodiumborohydride, lithium aluminium hydride or sodium (bisethoxymethoxy) aluminium hydride The compound of Formula XLII can undergo deprotection (path c, when Rj and Rj together joins to form where P1 is -C(=O)OC(CH3)3) to give a compound of Formula XLVII, which can be carried out in an organic solvent, such as, for example, methanol, ethanol, propanol or isopropylalcohol, in the presence of an alcoholic acid solution, such as, for example, methanolic hydrochloric acid or ethanolic hydrochloric acid. The compound of Formula XLII can undergo deprotection (when Rj and Rj together joins to form Np< where P1 is -C(=O)OC(CH3)2CHBr2) to give a compound of Formula XLVII, which can be carried out in an organic solvent, such as, for example, ethanol, methanol, propanol or isopropylalcohol, or by hydrobromide in acetic acid. The compound of Formula XLII can undergo deprotection (when Rj and Rj together joins to form to give a compound of Formula XLVII, which can be carried out by a supernucleophile, such as, for example, lithium cobalt (I) plithalocyanine, zinc and acetic acid or cobalt phthalocyanine. The reaction of a compound of Formula XLVII with a compound of Formula XII (path cl) to give a compound of Formula XLVIII can be carried out in an organic solvent, such as, for example, dimethylformamide, tetrahydrofuran, diethylether or dioxane in the presence of a base such as, for example, N-methylmorpholine, triethylamine, diisopropylethylamine or pyridine. The reaction of a compound of Formula XLVII with a compound of Formula X (path c2) to give a compound of Formula XLIX can be carried out in an organic solvent, such as, for example, dichloroethane, dichloromethane, chloroform or carbon tetrachloride in the presence of a base such as, for example, triethylamine, diisopropylethylamine, N- methylmorpholine or pyridine. The compound of formula XLII (path d, when Rj1 and Rj together joins to form ° ) can undergo reduction to give a compound of Formula L, in an organic solvent for example, toluene, benzene or xylene with reducing agent, such as, for example, diisobutylaluminium hydride, sodiumborohydride or lithium aluminium hydride. The reaction of a compound of formula XLII (path e, when Rh and Rj together joins to form ° ) with a compound of Formula LI to give a compound of Formula LII can be carried out in an organic solvent for example methanol, ethanol, propanol or isopropylalcohol. The reaction of a compound of Formula LII with a compound of Formula X to give a compound of Formula LIII can be carried out in an organic solvent, such as, for example, dichloroethane, dichloromethane, chloroform or carbon tetrachloride in the presence of a base, such as, for example, triethylamine, diisopropylethylamine, N- methylmorpholine or pyridine. The compound of Formula LIII can undergo cyclisatioii to give a compound of Formula LIV in an organic solvent, such as, for example, dimethylformamide, tetrahydrofuran, diethylether or dioxane, in the presence of a base, such as, for example, potassium carbonate, sodium carbonate or lithium carbonate. The reaction of a compound of Formula XLII (path f) can be reacted with hydrazine hydrochloride to give a compound of Formula LIVa in an organic solvent, such as, for example, ethanol, methanol, propanol or isopropylalcohol. Some representative compounds which can be prepared following Scheme VI include: 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.4]non-2-ene (Compound No. 11), Ethyl 8-benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2- ene-4-carboxylate (Compound No. 36), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-ene-4-carboxylic acid (Compound no. 37), Ethyl 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-ene-4- carboxylate (Compound No. 39), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,6a-dimethyl-3a/7-cyclopenta[(H]isoxazole- 4,6(5H",6aH)-dione (Compound No. 43), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-6,6a-dihydrofuro[3,4-(f]isoxazol-4(3aH)-one (Compound No. 45), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l,8-dioxa-2-azaspiro[4.5]dec-2-ene (Compound No. 52), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3aH-cyclopenta[cyclopentanecarboxamide ("Compound No. 47) To a solution of the compound hydrochloride salt of 3-(3-cyclopentyloxy-4- methoxy-phenyl)-l-oxa-2-aza-spiro[4.5]dec-2-en-8-ylamine (disclosed in U.S. Patent Application No. 10/930,569) (lOOmg, 0.260 mmol) in dimethylformamide (1 mL) was added cyclopentylcarboxylic acid (0.025 ml, 0.236 mmo Ie). The reaction mixture was cooled to 00C stirred followed by the addition of N-methylmorpholine (0.0318 ml, 0.289 mmol) and hydroxybenzotriazole 39 mg, 0.289mmole). The resulting mixture was stirrred for 30 minutes at the same temperature followed by the addition of l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (55 mg, 0.289 mmol). The mixture was again stirred for 10 hours. The resulting mixture was diluted with water and extracted with ethyl acetate. The organic extracts were separated, washed with water and brine and dried over anhydrous sodium sulphate. They were then filtered and concentrated under reduced pressure and the residue thus obtained was purified by column chromatography using 5% methanol in ethyl acetate solvent mixture as eluent to furnish the title compound. Yield: 80 mg. Mass (m/z): 441.34 (M++l). The following compounds can be prepared analogously, N-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-yl}-2- fluorobenzamide (Compound No. 138) Mass (m/z): 467.0 (M++l), N-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8- yl}benzamide (Compound No. 139) Mass (m/z): 449.0 (M++l). Example lό: N-(3-r3-fCvclopentyloxγV4-methoχyphenyl1-l-oxa-2-a7:aspiror4.51dec-2- en-8-vUmethanesulfonamide (Compound No. 58") To a solution of the compound hydrochloride salt of 3-(3-cyclopentyloxy-4- methoxy-phenyl)-l-oxa-2-aza-spiro[4.5]dec-2-en-8-ylamine (disclosed in our copending patent application US serial No. 60/498,947) (0.17 gm, 0.45 mmole) in dichloromethane (50 mL) was added triethylamine (0.13 ml, 0.090 mmole) at room temperature followed by the addition of methane sulphonylchloride (0.05 ml, 0.58mmole). The reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was quenched with aqueous sodium bicarbonate solution and extracted with ethyl acetate followed by the removal of dichloromethane under reduced pressure. The organic extracts were separated, washed with water and brine and dried over anhydrous sodium sulphate. They were then filtered and concentrated under reduced pressure to furnish the title compound. Yield: 70 mg. Example 17: S-rS-CCvclopentyloxy^^-methoxyphenv^-Sa^.S^JJa-hexahydro-l^- benzisoxazole (Compound No. 56) To a solution of the compound 3-(cyclopentyloxy)-4-methoxybenzaldehyde oxime (disclosed in our copending patent application US serial No. 60/498,947) (0.26g, l.l lmmol), cyclohexene (0.091g, 1.11 mmol), 3 to 4 drops of pyridine in 20% chloroform in dichloromethane (50 ml) was added sodium hypochlorite (4%, 2.5 ml, 1.33 mmol) under nitrogen atmosphere. The resulting reaction mixture was stirred at room temperature for 18 hours followed by the addition of aqueous sodium hypochlorite (4%, 2.5 ml, 1.33 mmol) drop wise again. The reaction mixture was again stirred for 36 hours, washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography to furnish the title compound. Yield: 0.10Og. Mass (m/z): 317 (M++l). The following compounds can be prepared analogously, 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.4]non-2-ene (Compound No. 11) Mass (m/z): 316.25 (M++l), Ethyl 8-benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2- ene-4-carboxylate (Compound No. 36) Mass (m/z): 493.33 (M++l), Ethyl 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-ene-4- carboxylate (Compound No. 39) Mass (m/z): 402.17 (M++l), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,6a-dimethyl-3aH'-cyclopenta[J]isoxazole- 4,6(5H,6aH)-dione (Compound No. 43) Mass (m/z): 406.25 (M++l), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-6,6a-dihydrofuro[3,4-rf]isoxazol-4(3aH)-one (Compound No. 45) Mass (m/z): 318.34. (M++l), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l,8-dioxa-2-azaspiro[4.5]dec-2-ene (Compound No. 52) Mass (m/z): 332.18 (M++l), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3aH-cyclopenta[(/]isoxazole-4,6(5/f,6aH)-dione (Compound No. 53) Mass (m/z): 332.30 (M++l), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-4,5,6,6a-tetrahydro-3aH-cyclopenta[J]isoxazole (Compound No. 57) Mass (m/z): 302.0 (M++l), 7ert-butyl 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-3a,4,6,6a-tetrahydro-5H-pyrrolo[3,4- d]isoxazole-5-carboxylate (Compound No. 142) Mass (m/z): 303.16 (M+H-BOC) 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,5,6,7a-tetrahydro-l,2-benzisoxazol-7(4H)- one (Compound No. 150) Mass (m/z): 330.10 (M++!). Example 18: 3-r3-(Cvclopentyloxy')-4-inethoxyphenyll-l-oxa-2-azaspiro[4.5]dec-2-ene- 4-carboχylic acid fCompound no. 37) Compound No. 39 (50 mg, 0.12mmole) was dissolved in ethanol (1.5 mL) and lithium hydroxide in water solution (16 mg, 0.37mmole) was added. The mixture was stirred for 4 hour at refluxing temperature. Solvent was removed under reduced pressure and the residue thus obtained was diluted with water and acidified with drop of concentrated hydrochloric acid. The organic compound was extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulphate and finally concentrated under reduced pressure to afford title organic compound with a yield of 32 mg. Mass (m/z): 374.20 (M++l). Example 19: 3 - [3 -(Cyclopentyloxy)-4-methoxyphenyl]-3 a A6,6a-tetrahvdrofuro [3 ,4- άTjisoxazole (Compound No. 44) Step α: Synthesis of {3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5-dihydroisoxazole- 4,5-diyl}dimethanoI But-2-ene- 1 ,4-diol (29 mg, 0.328mmole) was added to the solution of the compound 3-(cyclopentyloxy)-4-methoxybenzaldehyde oxime (70 mg, 0.298mmole) in tetrahydrofuran (10 mL), and the resulting reaction mixture was stirred at room temperature. Sodium hypochlorite (1 mL) was added slowly to the mixture thus obtained over the period of 20 minutes and the reaction mixture was allowed to stir at room temperature overnight. A second lot of sodium hypochlorite (ImL) was again added to it and stirred for 2 hours at room temperature. Tetrahydrofuran was evaporated off and the organic compound was extracted with ethyl acetate twice. The organic layer was concentrated to yield the title compound with a yield of 25 mg. Step b: Synthesis of 3-[3-(CycIopentyloxy)-4-methoxyphenyl]-3a,4,6,6a- tetrahydrofuro[3,4-rf]isoxazole A solution of the compound obtained from step a above (lOOmg, 0.0003 lmole) in acetic anhydride (10 ml) was refluxed for 100-11OC for 12 hours. The reaction mixture was diluted with water and extracted with ethyl acetate, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography using 10% ethyl acetate in hexane solvent mixture as eluent to furnish the title compound. Yield: 65 mg. Mass (m/z): 304.38 (M++!). Example 20: 3-r3-(cvclopentyloxy)-4-methoxyphenyl1-lJ-dioxa-2-azaspiro[4.41non-2- en-8-one (Compound No. \5) To a suspension of chromic anhydride (3.6 g, 35.82 mmol) in dichloromethane (20 ml) was added pyridine (5.66g, 71.64 mmol) and stirred the reaction mixture for 15 minutes at room temperature. To it was added a solution of the compound 2-[3-[3- (cyclopentyloxy)-4-methoxyphenyl]-5-(hydiOxymethyl)-4,5-dihydroisoxazol-5-yl]ethanol (disclosed in our copending patent application US serial No. 60/498,947) (1.Og, 2.99 mmol) in dichloromethane (5 ml) and stirred the reaction mixture for 1 hour. The solvent was evaporated under reduced pressure and the mixture was filtered through celite pad. The filterate was concentrated under reduced pressure and the residue thus obtained was purified by column chromatography to furnish the title compound. Yield: 230mg. Mass (m/z): 332.17 (M++l). Example 21 : 3-[3-(cvclopentyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-en- 8-ol ("Compound No. 16) A solution of the Compound No. 15 (30mg, 0.09 mmol) in dry toluene (5 ml) was cooled to -780C followed by the addition of diisobutylaluminium hydride (19.3 mg, 0.14 mmol) dropwise and stirred the reaction mixture at same temperature for 2 hours under argon atmosphere. To it was added sodium potassium tartarate solution followed by ethyl acetate and water. The organic layer was separated, washed with brine and water, dried over anhydrous sodium sulphate and concentrated under reduced pressure to furnish the title compound. Yield: 18 mg. Mass (m/z): 334 (M++l). Example 22: 3-[3-(Cycloρentyloxy)-4-methoxyphenyll-4,5,6,6a-tetrahydro-3aH- pyrrolof3,4-6r|isoxazole (Compound No. 140) To a solution of the Compound No. 142 (120mg) in dichloromethane (5ml) at 0°C was added methanolic hydrochloric acid (ImI) dropwise and stirred the reaction mixture for overnight. The solvent was evaporated under reduced pressure and the residue thus obtained was recrystallised with dichloromethane in hexane (20:80) solvent mixture as eluent to furnish the title compound. Yield: 100 mg. Mass (m/z): 303.99 (M++l). Examϋle 23 : 5-Acetyl-3-r3-("cvclopentyloxy')-4-methoxyphenyll-4.5.6.6a-tetrahvdro-3aH- pyrrolo[3,4-(f|isoxazole (Compound No. 147) The compound No. 140 (45 mg, 0.149 mmole) and acetic anhydride (18.25 mg, 0.1788mmole) were taken in dichloromethane (6 ml) followed by the addition of catalytic amount of dimethylamino pyridine was added and stirred for overnight. The resulting reaction mixture was diluted with water (15ml) and extracted with dichloromethane. The organic layer was separated, washed with brine and water, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography to furnish the title compound. Yield 36 mg. Mass (m/z): 345.0 (M++l). Example 24: 3-[3-(Cvclopentyloxy)-4-methoxyphenyl]-5-(methylsulfonyl)-4,5,6,,6a- tetrahvdro-3aH-pyrrolor3,4--4-methoχyphenylVl,7-dioxa-2- azaspiror4.41non-2-ene ("Compound No. 154) The title compound was synthesised by following the procedure as described for the synthesis of (Compound No. 137) by using the compound 3-(benzyloxy)cycloρentyl methanesulfonate in place of cyclopentene oxide. Mass (m/z): 424.07 (M++l). The following compound was prepared analogously, Hydrochloride salt of 3-[4-methoxy-3-(piperidin-3-yloxy)phenyl]-l,7-dioxa-2- azaspiro[4.4]non-2-ene (Compound No. 163) Mass (m/z): 331.1 (M+- HCl). 3- {3-[(2,6-Dichloropyridin-4-yl)methoxy]-4-methoxyphenyl} -1 ,7-dioxa-2- azaspiro[4.4]non-2-ene (Compound No. 167) Mass (m/z): 408.8 (M++l). Example 33 : 2-fDifluoromethoxy)-5-(l ,7-dioxa-2-azaspiro|~4.4"|non-2-en-3-vDphenol (Compound No. 41) Step a: Synthesis of 3-(benzyloxy)-4-(difluoromethoxy)benzaIdehyde oxime Hydroxylamine hydrochloride (1.50 g, 21.58mmole) and sodium acetate (1.769g, 21.573mmole) was added to a stirred solution of compound 4-(difluoromethoxy)-3- phenoxybenzaldehyde (1.5Og, 5.395 mmole) in ethanol (10 mL). The reaction mixture was stirred at room temperature for 3-4 lirs. Ethanol was evaporated under reduced pressure, which was diluted with water (20 mL) and the organic compound was extracted with ethyl acetate (2x15 mL). The ethyl acetate layer was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford the title compound. Step b: Synthesis of methyl 3-[3-(benzyIoxy)-4-(difluoromethoxy)phenyl]-5-(2- methoxy-2-oxoethyl)-4,5-dihydroisoxazoIe-5-carboxylate Dimethyl 2-methylenesuccinate (1.078g, 6.824mmole) was added to the solution of compound obtained from step a above (1.0Og, 3.412mmole) in tetrahydrofuran (5mL), and the resulting reaction mixture was stirred at room temperature. Sodium hypochlorite (10 mL) was added slowly to the mixture thus obtained over the period of 20 minutes and the reaction mixture was allowed to stir at room temperature overnight. Tetrahydrofuran was evaporated off and the organic compound was extracted with ethyl acetate twice. The organic layer was concentrated to yield the title compound with a yield of 1.50 g. Step c: Synthesis of 2-[3-[3-(benzyloxy)-4-(difluoromethoxy)phenyl]-5- (hydroxymethyl)-4,5-dihydroisoxazol-5-yl]ethanol The compound obtained from step b above (1.5g, 3.340mmole) was dissolved in tetrahydrofuran (10 mL) and lithium hydroxide in water solution (0.68 mL of 0.5 M aqueous solution, 16.682 mmoles, 5 eq) was added. The mixture was stirred for 1 hour at room temperature. The mixture was stirred for 5 hrs at 55-600C. Solvent was removed under reduced pressure and the residue thus obtained was diluted with water and acidified with drops of concentrated hydrochloric acid. The organic compound was extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulphate and finally concentrated under reduced pressure to afford title organic compound with a yield of 1.103g. Step d: Synthesis of 2-[3-[3-(benzyloxy)-4-(difluoromethoxy)phenyl]-5- (hydroxymethyl)-4,5-dihydroisoxazoI-5-yl] ethanol The compound obtained from step c (1.1 g, 2.428mmole) was taken in tetrahydrofuran (7 ml) followed by the addition of sodium borohydride (0.276g, 7.26mmole) at 0-50C and boron trifiuoride etherate (1.02g, 7.28mmole) was added dropwise and stirred for 14hrs at room temperature. Solvent was removed under reduced pressure, water was added and extracted with ethylacetate. The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography to furnish final product with the yield 0.732 g. Step e: Synthesis of 3-[3-(benzyloxy)r4-(difluoromethoxy)phenyl]-l,7-dioxa-2- azaspiro[4.4]non-2-ene To a solution of the compound obtained from step d above (1 eq) in tetrahydrofuran, triphenylphosphine (1.12 eq) and succinimide (1 eq), was added diisopropyldiazadicarboxylate (1.14 eq). The reaction mixture was stirred at room temperature for overnight. The organic solvent was removed under reduced pressure and the residue thus obtained was purified by column chromatography to furnish the title compound. Yield: 40 %. Step f: Synthesis of 2-(difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3- yl)phenol (Compound No. 41) To a solution of the compound obtained from step e above (0.20Og, 0.53mmole) in methanol (1OmL), was added palladium on carbon (300mg, 10%). The reaction mixture was evacuated with hydrogen gas and the resulting reaction mixture was allowed to stir at room temperature for 1 hour under hydrogen atmosphere. The reaction mixture was filtered through celite pad. The filtrate was concentrated under reduced pressure to furnish the title compound. Yield = 60 mg. Mass (m/z): 286.03 (M++l). Example 34: (S)-3-[3-("cyclopentyloxy')-4-methoxyphenyl1-U-dioxa-2-azaspiror4.41non- 2-ene (Compound No. 124) Step a: Synthesis of L-Ephedrine salt of 5-(carboxymethyl)-3-[3-(cyclopentyloxy)-4- methoxyphenyI]-4,5-dihydroisoxazole-5-carboxylic acid 5 -(carboxymethyl)-3 - [3 -(cyclopentyloxy)-4-methoxyphenyl] -4,5- dihydroisoxazole-5-carboxylic acid (disclosed in our copending patent application U.S. serial No.60/498,947) (1.0 g, 2.87 mmol) and L-Ephedrine (0.95 g, 5.73 mmol) were dissolved in acetone (50 ml) and the mixture was refluxed for 4 h. The reaction mixture was slowly brought to room temperature (35 0C) and kept as it is for 24-36 hours to furnish the S-isomer. Yield: 0.3 g. Step b: Preparation of (S)-methyl 3-[3-(cycIopentyloxy)-4-methoxyphenyl]-5-(2- methoxy-2-oxoethyl)-4,5-dihydroisoxazole-5-carboxylate Thionyl chloride (0.80 ml, 11.1 mmol) was added slowly to a dry- methanol (50 mL) at 0 0C under nitrogen atmosphere and stirred for 1 hour followed by the addition of solution of the compound obtained from step a above (1.88 g, 2.77 mmol) in dry-methanol (50 mL) at O0C. The reaction mixture was slowly brought to room temperature and stirred at that temperature for 12 hours. The reaction mixture was concentrated and diluted with dichloromethane. The organic portion was washed with water, brine and dried over sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography to furnish the title compound. Yield: 0.92 g. m.p.: 92- 93 0C; [α]D = -113.9° (C, 1.17, CH3OH). 1H NMR (CDCl3) δ 7.35 (s, 1 H), 7.05 (d, J= 0.02 Hz, 1 H), 6.85 (d, J= 0.02 Hz, 1 H), 4.81 (m, 1 H), 4.00 (d, J= 0.04 Hz, 1 H), 3.88 (s, 3 H), 3.82 (s, 3 H), 3.72 (s, 3 H), 3.48 (d, J= 0.04 Hz, 1 H), 3.27 (d, J= 0.04 Hz, 1 H), 3.00 (d, J= 0.04 Hz, IH), 1.95 (m, 2 H), 1.88 (m, 4 H), 1.63 (m, 2 H). Mass (m/z): 393 (M++l). Step c: Synthesis of (S)- 2-[3-[3-(cyclopentyloxy)-4-methoxyphenyl]-5- (hydroxymethyI)-4,5-dihydroisoxazol-5-yl]ethanol The compound obtained from step b above (0.85 g, 2.17 mmol) was dissolved in tetrahydrofuran (100 niL) and cooled to 0 0C and sodium borohydride (0.41 g, 10.9 mmol) was added portion wise. The reaction mixture was stirred for 1 hour followed by the addition of methanol (10 mL). The reaction mixture was stirred for 10 hour at room temperature. Reaction mixture was filtered and the solid thus obtained was washed with tetrahydrofuran. The organic solution was cooled to 0 0C and saturated ammonium chloride solution was added slowly over a period of 30 minutes. The reaction mixture was concentrated and diluted with ethyl acetate (100 mL). The organic portion was washed with saturated ammonium chloride solution, water and brine, dried over sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography to furnish the title compound. Yield: 0.5 g. m.p.: 108-109 0C. [α]D = -5.32° ( c, 1.17, CH3OH). 1H NMR (CDCl3) δ 7.33 (s, 1 H), 7.04 (d, J= 0.02 Hz, 1 H), 6.84 (d, J= 0.02 Hz, 1 H), 4.81 (m, 1 H), 3.92-3.83 (m, 2 H), 3.85 (s, 3 H), 3.72 (m, 2 H), 3.41 (d, J= 0.04 Hz, 1 H), 3.20 (d, J= 0.04 Hz, 1 H), 2.40 (bs, 2 H, -OH), 2.07 (m, 2 H), 2.05-1.83 (m, 6 H), 1.63- 1.61 (m, 2 H). Mass (m/z): 336 (M++l). Step d: Synthesis of (S)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l,7-dioxa-2- azaspiro[4.4]non-2-ene (Compound No. 124) To a solution of the compound obtained from step c above (0.43 g, 1.28 mmol), triphenyl phosphine (0.37 g, 1.41 mmol) and succinimide (0.14 g, 1.41 mmol) was added dry tetrahydrofuran (20 mL) and stirred the reaction mixture for 20 minutes at room temperature which was subsequently cooled to O0C. Diisopropylazodicarboxylate (0.30 mL, 1.54 mmol) was added slowly over a period of 10 minutes at 0 0C and further stirred the reaction mixture at room temperature for overnight. The reaction mixture was concentrated under reduced pressure. The residue thus obtained was purified by column chromatography to furnish the title compound. Yield: 0.28 g. m.p.: 110.5 0C. [α]D = +1.76° (c, 1.19, CH3OH). 1H NMR (CDCl3) δ 7.37 (s, 1 H), 7.00 (d, J= 0.02 Hz, 1 H)5 6.85 (d, J= 0.02 Hz, 1 H), 4.82 (m, 1 H), 4.10 (d, J= 0.03 Hz, 1 H), 4.03 (m, 2 H), 3.88 (s, 3 H), 3.82 (d, J= 0.03 Hz, 1 H), 3.37 (s, 2 H), 2.06 (m, 1 H), 1.97-1.62 (m, 7 H), 1.61 (m, 2 H); Mass (m/z): 319 (M++l). The following compound can be prepared analogously by using D-Ephidrine in place of L-Ephidrine, (R)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 30) Mass (m/z): 319 (M++l). Example 35: 4-Bromo-3-[3-fcyclopentyloxyV4-methoxyphenyl]-l,7-dioxa-2- azaspiror4.4]non-2-ene (Compound No. 149) To a solution of the compound 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l,7- dioxa-2-azaspiro[4.4]non-2-ene (disclosed in our copending patent application US Serial No. 60/498,947) (lOOmg, 0.32mmol) in chloroform (5ml) was added N- bromosuccinimide (84mg, 0.47mmol) and azobutyronitrile (lOmg, 0.06mniol). The reaction mixture was stirred for 2 hours and subsequently diluted with water. The mixture was extracted with dichloromethane, washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified with column chromatography to furnish the title compounds. Yield: 40 mg. Mass (m/z): 395.97 (M++l, Compound No. 149). Example 36: 3-r3-rcvclopentyloxy)-4-methoxyphenyll-l,7-dioxa-2-azaspiro[4.41non-2-en- 4-ol CCompound No. 29~) Step a: Synthesis of 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l,7-dioxa-2- azaspiro[4.4]non-2-en-4-yϊ acetate To a solution of the 3-[3-(cyclopentyloxy)-4-methoxyphenyi]-l,7-dioxa-2- azaspiro[4.4]non-2-ene which is disclosed in our copending patent application US Serial No. 60/498,947 (lOOmg, 0.26mmol) in dimethylformamide (5ml), was added sodium acetate (104mg, 1.26mmol) and stirred the mixture at HO0C for 14 hours. The resulting reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to furnish the title compound. Yield: 1 lOmg. Step b: Synthesis of 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l,7-dioxa-2- azaspiro[4.4]non-2-en-4-oI To a solution of the compound obtained from step a above (42mg, 0.1 lmmol) in methanol (2ml) was added potassium carbonate (46mg, 0.34mmol) under argon atmosphere and stirred the reaction mixture for 30 minutes at room temperature. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue thus obtained was purified by column chromatography to furnish the title compound. Yield: 28mg. Mass (m/z): 334.13 (M++l). PDE-IV Enzyme Assay The efficacy of compounds as PDE-4 inhibitor was determined by an enzyme assay (Burnouf et al. ; J. Med. Chem. , 2000, 43 :4850-4867). The PDE-4 enzyme source used was U937 cell cytosolic fraction prepared by sonication. The enzyme reaction was carried out, with the cytosolic fraction as the enzyme source, in the presence of cAMP (1 μM) at 30 0C in the presence or absence of NCE for 45 - 60 min. An aliquot of this reaction mixture was taken further for the ELISA assay to determine level of cAMP in the sample. The concentration of the cAMP in the sample directly correlates with the degree of PDE-4 enzyme inhibition. Results were expressed as percent control and the IC50 values of test compounds were reported to be in the range of about μM to low fM. For example, the IC50 for PDE-IV inhibition ranged from about 1 μM to about 100 fM, or from about 600 nM to about 100 fM, or from about 400 nM to about 100 fM, or from about 200 nM to about 100 fM, or from about 100 nM to about 100 fM, or from about 75 nM to about 100 fM, or from about 1 nM to about 100 fM, as compared to rolipram (about 480 nM 5 repetitions). Compound No. 119 was not tested as it was insoluble under the experimental conditions. CeII based Assay for TNF-α release Method of isolation of Human Peripheral Blood Mononuclear Cells: Human whole blood was collected in vacutainer tubes containing heparin or EDTA as an anti coagulant. The blood was diluted (1:1) in sterile phosphate buffered saline and 10 ml. was carefully layered over 5 ml Ficoll Hypaque gradient (density 1.077 g/ml) in a 15 ml conical centrifuge tube. The sample was centrifuged at 3000 rpm for 25 minutes in a swing-out rotor at room temperature. After centrifugation, interface of cells were collected, diluted at least 1 :5 with PBS and washed three times by centrifugation at 2500 rpm for 10 minutes at room temperature. The cells were resuspended in serum free RPMI 1640 medium at a concentration of 2 million cells/ml. Alternatively whole blood was used. LPS stimulation of Human PBMNCs : PBMN cells (0.1 ml ; 2 million/ml) were co-incubated with 20 μl of compound (final DMSO concentration of 0.2 %) for 10 min in a flat bottom 96 well microtiter plate. Compounds were dissolved in DMSO initially and diluted in medium for a final concentration of 0.2% DMSO. LPS (1 μg/ml, final concentration) was then added at a volume of 10 μl per well. After 30 min, 20 μl of fetal calf serum (final concentration of 10%) was added to each well. Cultures were incubated overnight at 370C in an atmosphere of 5% CO2 and 95% air. Supernatant were then removed and tested by ELISA for TNF-α release using a commercial kit (e.g. BD Biosciences). For whole blood, the plasma samples were diluted 1 :20 for ELISA. The level of TNFα in treated wells was compared with the vehicle treated controls and inhibitory potency of compound was expressed as IC50 values calculated by using Graph pad prism. Compounds 29, 33, 39, 52, 56, 57, 60, 61, 140, 148, 151, 154, 157 and 164 exhibited IC50 in the TNF assay of from about 10 μM to about 0.27 nM, or from about 200 nM to about 0.24 nM, or from about 130 nM to about 0.24 nM, or from about 12 nM to about 0.24 nM, as compared to rolipram (about 240 nM, 4 repetitions). WE CLAIM: A compound having the structure of Formula I, (Formula Removed) and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates. enantiomers, diastereomers or N-oxides, wherein R1 and R2 together forms an optionally substituted cycloalkyl or heterocyclyl ring wherein one or more optional substituent are oxo, alkyl, alkaryl, alkenyl, alkynyl, helerocyclylalkyl, cycloalkylalkyl, -SO2NRxRy, halogen. -NH2, -(CM2)gC'(=O)NRxRy-. - NI-I('(=O)OR6, -NHC(=O)NRxRy, -C(=O)OR3, -NHC(=O)RX, -SO2R.i, cyano, hydroxy, alkoxy. substituted amino, -C(=O)R3; R4 is hydrogen; alkyl; hydroxy; halogen; carboxy; R7 is hydrogen; alkyl; RI is independently hydrogen or alkyl and R2 and R.J forms an optionally substituted 4-12 membercd saturated or unsaturated monocyclic or bicyclic ring system fused to ring 3 having 0-4 heteroalom(s) selected from the group consisting of N, O and S, wherein the substituents is one or more of oxo, alkyl, -C(=O)OR3, -SO2R3. halogen, hydroxy, alkoxy, - NH2 or substituted amino, with the proviso that R2 and R4 together does not form -CH2-O- C'H2-O-CH2-; X| and \2 is hydrogen, alkyl. cycloalkyl, alkaryl, alkenyl, cycloalkylalkyl. heteroaryl. hetrocyclyl. heteroarylalkyl. heterocyclylalkyl, -(CM2)gC(=O)NRXRy or (CH2)glC(=O)OR3 (wherein g is an integer from 0-3 and gl is an integer from 1-3); X1 and X2 together can optionally form a cyclic ring fused with the ring A shown in formula 1. the ring containing 3-5 carbon atoms within the ring and having 2-3 heteroatoms selected from the group consisting of N. O and S; wherein R3 is alkyl. cycloalkyl or heterocyclyl; wherein the halogen is F. Cl, Br, or 1; Rx and Ry each independently is hydrogen, alkyl, C3-C6 alkenyl. C3-C6 alkynyl, carboxy, cycloalkyl. -S(O)mR5. aryl. alkaryl, heteroaryl. heterocyelyl. heteroarylalkyl, and heterocyclylalkyl; m is an integer between 0-2; R6 is alkyl. alkenyl, alkynyl, cycloalkyl, alkaryl, heteroarylalkyl or heterocyclylalkyl; wherein R5 is hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, alkaryl, heteroaryl, heleroarylalkyl, heterocyclyl or heterocyclylalkyl. A compound which is selected from 3- 3-(cyclopentyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-en-6-ol (Compound No. 1). 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-N-(4-fluorophenyl)-1 -oxa-2,7- diazaspiro|4.4]non-2-ene-7-carboxamide (Compound No. 2), 3-|3-(Cyclopentyloxy)-4-methoxyphenyl]-7-(tetrahydrofuran-3-ylcarbonyl)-l-oxa-2,7- diazaspiro|4.4|non-2-ene (Compound No. 3), 3- [3-(cyclopentyloxy)-4-metlioxyphenyl]-N,N-dimethyl-l-oxa-2,7-diazaspiro[4.4]non-2- ene-7-sulfonamide (Compound No. 4). N-butyl-3-|3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-ene-7- carboxamide (Compound No. 5), 2-|3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-en-7- yl }acetamide (Compound No. 6), Hydrochloride salt of 3-[3-(cyclopemyloxy)-4-rnethoxyphenyl]-8-prolyl-l-oxa-2,8- diazaspiro[4.5]dec-2-ene (Compound No. 7), 3-|3-(Cyclopentyloxy)-4-methoxyphenyl]-8-(2-morpholin-4-yl-ethyl)-l-oxa-2,8- diazaspiro[4.5]dec-2-ene (Compound No. 8), N-butyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspirof4.5]dec-2-ene-8- carboxamide (Compound No. 9), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-8-(methylsulfonyl)-l-oxa-2,8- diazaspiro|4.5]dec-2-ene (Compound No. 10), 3- 3-(cyclopentyloxy)-4-methoxyphenyl]-l -oxa-2-azaspiro[4.4]non-2-ene (Compound No. 11). 3-[3.4-bis(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4Jnon-2-ene (Comp No. 12). 3-(3,4-diisopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 13), 3-3-methox)-4-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 14), 3-[3-(cyclopcntyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-en-8-one (Compound no. 1 5), 3-[3-(cyclopcntyloxy)-4-niethoxyphenyl]-l,7-dioxa-2-azaspiro|4.4]non-2-en-8-ol (Compound No. 16). 3-[3-(Cyclopentyloxy)-4-methoxyphenylj-7-isopropyl-l-oxa-2,7-diazaspiro[4.4]non-2-ene (Compound No. 17), 3-[ 3-(cyclopentyloxy)-4-methoxyphenyl]-7-(cyclopropylcarbonyl)-1-oxa-2.7- diazaspiro[4.4]non-2-ene (Compound No. 18), N-bcnzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-ene-7- carboxamide (Compound No. 19), 7-acclyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-ene (Compound No. 20), Tert-butyl 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.5]dec-2-ene- 7-carboxylate (Compound No. 21), N-butyl-N'-(3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8- yl] urea (Compound No. 22). N-{3- [3-(cyclopcniyloxy)-4-niethoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-yl]-N-(2- methoxyphenyl)urea (Compound No. 23), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-ol (Com No. 24), Hydrochloride salt of 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,7- drazaspiro|4.5|dec-2-ene (Compound No. 25), 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-one (Conipound No. 26). 3-[3.4-bis(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 27). 3[|3,4-Bis(cyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 28). 3- 3-(cyclopeniyloxy)-4-methoxyphenyl|-l,7-dioxa-2-a7.aspiro[4.4]non-2-en-4-ol (Compound No. 29). (R)-3-[3-(cyclopcntyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Conipound No. 30), 3-[3-(Cyclopfntyloxy)-4-methoxyphenyl]-8-(cyclopropylmethyl)-1 -oxa-2,8- dia/.aspiro[4.5Jdec-2-ene (Compound No. 31), N-Benzyl-3-|3-(cyclopenlyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5|dec-2-ene-8- carboxainide (C'onipound No. 32). 3-[3.4-Bis(benzyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4)non-2-ene (Compound No. 33). 4-( 1.7-I)ioxa-2-a7.aspiro(4.4]non-2-en-3-yl)benzene-l,2-diol (Compound No. 34). 7-Amino-3-|3-(cyclopentyIoxy)-4-methoxyphenyl]-l-oxa-2,7-diazaspiro[4.4]non-2-en-6- one (Compound No. 35). Ethyl 8-benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2.8-diazaspiro[4.5]dec-2- ene-4-carboxylate (Compound No. 36), 3[|3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-ene-4-carboxylic acid (Compound no. 37), 8-Benzyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 38), Ethyl 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspirof4.5]dec-2-ene-4- carboxylale (Compound No. 39), 3-3-(Difluoromethoxy)-4-methoxyphenyl]-1.7-dioxa-2-azaspiro[4.4]non-2-ene (Com No. 40). 2-(Difluoromethoxy)-5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol (Compound No. 41) 3-[3-(Cyclopentyloxy)-4-methoxyphenyr]-l-oxa-2,7-diazaspiro[4.4]non-2-en-6-one (Compound No. 42). 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,6a-dimethyl-3aH-cyclopenta[d]isoxazole- 4.6(5H,6aH)-dione (Compound No. 43). 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,4,6,6a-tetrahydrofuro[3.4-d]isoxazole (Compound No. 44). 3-|3-(C'yclopentyloxy)-4-methoxyphenyl]-6,6a-dihydrorurof3,4-d]isoxazol-4(3a/y)-one (Compound No. 45), Tert-butyl |( 3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5jdec-2-en-8- yl{amino)carbonyl]carbamate (Compound No. 46), N-{3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8- yl] cyclopentanecarboxamide (Compound No. 47), 8-Acetyl-3-|3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2.8-diazaspiro[4.5]dec-2-ene (Compound No. 48), 8-(Cyclopcntylcarbonyl)-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8- diazaspiro[4.5Jdec-2-ene (Compound No. 49), 3-[ 3-(Cyclopentyloxy)-4-methoxyphenyl]-8-(2-piperidin-l-ylethyl)-l-oxa-2.8- diazaspiro|4.5|dec-2-ene (Compound No. 50), 3-(2.3-Dihydro-1.4-bcnzodioxin-6-yl)-1.7-dioxa-2-a7.aspiro[4.4]non-2-ene (Compound NO. 51). 3-[ 3-(Cyclopentyloxy )-4-methoxyphenyl]-1,8-dioxa-2-azaspiro[4.5]dec-2-ene (Compound No. 52), 3-[3-(Cyclopenlyloxy)-4-methoxyphenyl]-3aH-cyclopenta[d]isoxazole-4,6(5H,6aH)-dione (Compound No. 53). 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-ethyl-l-oxa-2,8-diazaspiro[4.5]dec-2-ene (Compound No. 54), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-8-vinyl-l-oxa-2-azaspiro[4.5]dec-2-en-8-ol (Compound No. 55), 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,4,5,6,7,7a-hexahydro-1.2-benzisoxazo!e (Compound No. 56). 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-4,5,6,6a-tetrahydro-3aH-cyclopenta[d]isoxazole (C'ompound No. 57), N-[3-|3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8- yl} methanesulfonamide(Compound No. 58), 3-|3-(Cyclopentyloxy)-4-methoxyphenyl]-8-methyl-l-oxa-2-azaspiro[4.5]dec-2-en-8-ol (Compound No. 59). 3-|3-(Allyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 60). 3-[3-(2-Chloroethoxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro|4.4]non-2-ene (C'ompound No. 61), 2-(Cyclopenlyloxy)-4-( 1.7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol (C'ompound No. 62). 3-(4-Butoxy-3-isobotoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (C'ompound No. 63). 3-(3-lsobutoxy-4-propoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 64). 3-|3-Butoxy-4-(cyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (C'ompound No. 65), 3-(3-Butoxy-4-ethoxyphenyl)-l ,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 66), 3-|3-Butoxy-4-(cyclohexyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (C'ompound No. 67). 3-|3-(Cyclohexylmethoxy)-4-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 68). 3-|3-(Cyclohexylmethoxy)-4-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 69), 3-[4-Btoxy-3-(cyclohexylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Com No. 70). 3-(4-Isohutoxy-3-isopropoxyphenyl)-1.7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 71), 3-(4-Butoxy-3-isopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 72). 3-[4-(Cyclohexylmethoxy)-3-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 73), 3-[3-lsopropoxy-4-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 74). 3-[3-(Cyclopropylmethoxy)-4-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 75), 3-[3-(Cyclopropylmethoxy)-4-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2- azaspiro[4.4]non-2-ene (Compound No. 76), 3-[4-Butoxy-3-(cyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 77). 3-[3-(Cyclopropylmethoxy)-4-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-enc (C'ompound No. 78), 3-(3-Isobutoxy-4-isopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 79). 3-[4-(Cyclopropylmethoxy)-3-isobutoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (C'ompound No. 80). 3-[ 4-(cyclohcxyloxy)-3-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 81) 3-[4-(Cyclohexylmethoxy)-3-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- ene (Compound No. 82), 3-[4-(C1yclopropylmethoxy)-3-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- cne (Compound No. 83), 3-[3-(Cyclopentyloxy)-4-isobutoxyphenyl]-1.7-dioxa-2-azaspiro[4.4Jnon-2-ene (Com No. 84). 3-[3-(Cyclopentyloxy)-4-ethoxyphenyl]-1.7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 85), 3-[3-(Cyclopropylmethoxy)-4-ethoxyphenyl]-1.7-dioxa-2-azaspiro[4.4]non-2-ene (C'ompound No. 86), 3-[4-(C'yclopentyloxy)-3-isobutoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 87). 3-[3-lsopropoxy-4-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-az.aspiro[4.4]non-2-ene (Compound No. 88). 3-(4-Ethoxy-3-isobutoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 89) 3-[3-(Cyclopentyloxy)-4-propoxyphenylJ-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 90), 3-[4-Butoxy-3-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 91). 3-[3-(Cyclopentyloxy)-4-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 92). 3-[3-(Cyclopentyloxy)-4-(cycloheptyloxy)phenyl]-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 93), 3-[3-(Cycclopcntyloxy)-4-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non- 2-cnc ('Compound No. 94), 3-[4-(Cyclohexylmethoxy)-3-isobutoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (C'ompound No. 95), 3-[4-(Cyclohexylniethoxy)-3-(cyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4Jnon- 2-cnc (Compound No. 96), 3-[3-(Cyclopropylmethoxy)-4-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 97), 3-[4-(Cyclopcntyloxy)-3-(cyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- cnc (Compound No. 98), 3-[4-(Cyclopropylmethoxy)-3-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-enc (Compound No. 99), 3-[4-(Cyclopcnlyloxy)-3-isopropoxyphenyl]-1.7-dioxa-2-azaspiro[4.4]non-2-enc(C'omp No. 100). 3-(3-lsopropoxy-4-propoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 101). 3-(4-Hthoxy-3-isopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 102). 3-[3-I3Liioxy-4-(2-morpholin-4-ylethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-cnc (Compound No. 103). 3-[3-Buloxy-4-(cyclopenlyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (C'omd No. 104). 3-(3-Butoxy-4-propoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 105), 3-(3-Butoxy-4-isopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No 106). 3-[3-(Cyclohexylmcthoxy)-4-propoxyphenyl]-l ,7-dioxa-2-azaspiro[4.4]non-2-enc (Compound No. 1 07), 3-[3-(Cyclohcxylmethoxy)-4-isobutoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (C'ompound No. 108), 3-[3-(Cyclohexylmethoxy)-4-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- ene (Compound No. 109), 3-[3-(Cyclohexylmethoxy)-4-(cyclopropylmethoxy)phenyl]-1.7-dioxa-2-azaspiro[4.4]non- 2-ene (Compound No. 110), 3- 4-(Cyclohexylmethoxy)-3-propoxyphenyl]-1.7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 111), 3-[4-(Cyclopropylmethoxy)-3-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 112), 3-[4-(Cyclopentyloxy)-3-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 113). 3-[4-(3-lsobutoxy)-3-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 114), 3-[3-(Cycloheplyloxy)-4-(cyclopropylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4|non-2- cue (Compound No. 115), 3-[3-(Cycloheptyloxy)-4-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 1 16). 3-[4-Butoxy-3-(cycloheptyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 117). 3-[ 3-(Cyclohepiyloxy)-4-isopropoxyphenyl]-l ,7-dioxa-2-azaspiro[4.4]non-2-ene(Comp No. 118). 3-|3-(Cycloheptyloxy)-4-(cyclopentyloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4|non-2-ene (Compound No. 119), 3-(3-Rthoxy-4-propoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 120), 3-[4-(Cycloheptyloxy)-3-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 121). 3-[4-(Cyclopropylmethoxy)-3-ethoxyphenylJ-l,7-dioxa-2-azaspiro[4.4]non-2-ene (C'ompound No. 122). 3-[4-(Cyclohexylmethoxy)-3-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene(Comp No. 123). (S)-3-[3-(cyclopenlyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (C'ompound No. 124 3-(3-lkiloxy-4-isobutoxyphenyl)-1.7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 125). 3-(3-Ethoxy-4-isopropoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 126), 3-|4-(C'yclopenlyloxy)-3-elhoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 127). 3-(4-Butoxy-3-ethoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 128), 3-(3-Ethoxy-4-isobutoxyphenyl)-1,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 129). 3-1 3-(Cyclohcplyloxy)-4-isobutoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Comp No. 130). 3-[ 3-(Cycloheptyloxy)-4-(cyclopentyloxy)phenyl]-1.7-dioxa-2-azaspiro[4.4]non-2-ene ( Compound No. 131). 3-[3-(Cycloheptyloxy)-4-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4Jnon-2-ene (Comp No. 132). 3-(4-Butoxy-3-propoxyphenyl)-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 133). 3-(4-Ethoxy-3-propoxyphenyl)-l ,7-dioxa-2-azaspiro[4.4Jnon-2-ene (Compound No. 134). 3-[4-(Morpholin-4-ylethoxy)-3-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-enc (C'ompound No. 135), 3-(4-Isopropoxy-3-propoxyphenyl)-1.7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 136). 2-| 5-( 1.7-Dioxa-2-azaspiro[4.4|non-2-en-3-yl)-2-methoxyphenoxy]cyclopentanol (Compound No. 137). N- [3-|3-(C'yclopcntyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8-yl} -2- nuorobenzamide (Compound No. 138). N-{3-(3-(cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2-azaspiro[4.5]dec-2-en-8- yl]benzamide (C'ompound No. 139). Vj 3-(C'yclopt'iilyloxy)-4-methoxyphenylJ-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4- c/|iso.\a/olc (Compound No. 140) 7-(C'yclopentylcarbonyl)-3-[3-(cyclopentyloxy)-4-methoxyphenyl|-l-oxa-2,7- diazaspiro|4.5]dec-2-ene (Compound No. 141), Tert-butyl 3-|3-(cyclopentyloxy)-4-methoxyphenyl]-3a,4,6.6a-tetrahydro-5H-pyrrolo|3,4- d]isoxazole-5-carboxylate (Compound No. 142), 3-1 3-(Cyclopentyloxy)-4-methoxyphenyl]-l-oxa-2,8-diazaspiro[4.5]dec-2-ene-8- carhoxamidc (Compound No. 143). N-Butyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl|-l-oxa-2.7-diazaspiro|4.5]dec-2-cne-7- carboxamide (Compound No. 144). 3-[3-(C'yclopentyloxy)-4-methoxyphenyl]-7-(methylsulfonyl)-l-oxa-2,7- diazaspiro|4.5|dec-2-ene (Compound No. 145). 3-[4-Methoxy-3-(pyridin-3-ylmethoxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (Compound No. 146). 5-Acetyl-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-4,5,6,6a-tetrahydro-3aH-pyrrolo[3.4- d[|isoxazole (C'ompound No. 147). 3-[3-(Cyclopenlyloxy)-4-inethoxyphenyl]-5-(methylsulfonyl)-4,5,6,6a-tetrahydro-3a/7- pyrrolo[3,4-d]isoxazole (Compound No. 148). 4-Bromo-3-[3-(cyclopentyloxy)-4-methoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2-ene (C'ompound No. 149) 3-[3-(Cyclopentyloxy)-4-methoxyphenyl]-3a,5,6,7a-tetrahydro-l,2-benzisoxazol-7(4H)- one (C'ompound No. 150). 3-[4-(l)inuoromethoxy)-3-(2,3-dihydro-lH-inden-2-yloxy)phenyl]-l,7-dioxa-2- a/.aspiro[4.4]non-2-ene (Compound No. 151), 3-[4-(C'yclopentyloxy)-3-(2,3-dihydro-1 H-inden-2-yloxy)phenyl]-1,7-dioxa-2- a/aspiro[4.4]non-2-ene (Compound No. 152). 3-[4-Butoxy-3-(2,3-dihydro-lH-inden-2-yloxy)phenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- ene (Compound No. 153). 3-( 3-113-( Benzylox)')cyclopentyl]oxy} -4-methoxyphenyl)-l ,7-dioxa-2-azaspiro[4.4]non- 2-one (C'ompound No. 154), 7-Acetyl-3-[3-(cyelopentyloxy)-4-methoxyphenyl]-l-oxa-2.7-diazaspiro[4.5]dec-2-ene (C'ompound No. 1 55), 3-[4-Methoxy-3-(pyridin-2-ylmethoxy)phenyl]-1.7-dioxa-2-azaspiro[4.4]non-2-ene (C'ompound No. 156). 3-[3-(2.3-l)ihydro-lH-inden-2-yloxy)-4-ethoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- cue (C'ornpound No. 157), 3-|3-(2.3-Dihydro-lH-inden-2-yloxy)-4-propoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non-2- eno (C'ompound No. 158), 3-[4-(C'yclopropylmethoxy)-3-(2,3-dihydro-lH-inden-2-yloxy)phenyl|-1 ,7-dioxa-2- azaspiro[4.4]non-2-ene (Compound No. 159), 3-|3-(2.3-Dihydro-lH-inden-2-yloxy)-4-isopropoxyphenyl]-l,7-dioxa-2-azaspiro[4.4]non- 2-ene (C'ompound No. 160). 2-(2.3-Dihydro-lH-inden-2-yloxy)-4-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)phenol (C'ompound No. 161), N-cyclopropyl-2-[5-(l,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2- methoxyphenoxyjacetamide (C'ompound No. 162). l lydrochloride salt of 3-[4-methoxy-3-(piperidin-3-yloxy)phenyl]-l,7-dioxa-2- azaspiro|4.4|non-2-ene (C'ompound No. 163), 2-[5-( 1.7-Dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetamide (Comp No. 164), Ethyl | 5-(1,7-dioxa-2-azaspiro[4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetate (Comp No. 165). [ 5-( 1,7-Dioxa-2-azaspiro|4.4]non-2-en-3-yl)-2-methoxyphenoxy]acetonitrile (Comp No. 166). 3-[3-[(2.6-Dichloropyridin-4-yl)methoxy]-4-methoxyphenyl)-l,7-dioxa-2- azaspiro[4.4]non-2-ene (Compound No. 167). 3 A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or 2 together with a pharmaceutically acceptable carrier, excipient or diluent. 4. Use ol'a therapeutically effective amount of a compound of claim 1 or 2 in the manufacture of a medicament for treating AIDS, asthma, arthritis, bronchitis, chronic obstructer pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis. Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osleoarthritis, ulcerative colitis or other inflammatory diseases in an animal or human. 5. I ;se ol'a therapeutically effective amount of a compound of claim 1 or 2 in the manufacture of a medicament for preventing, inhibiting or suppressing inflammatory condition in an animal or human. 6. A method for preparing compounds of Formulae VII, IX. XI, XIII and XV. their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diaslereomers or N-oxides wherein the method comprises the steps of: a. N-protecting a compound of Formula 1 (Formula Removed) to give a compound of Formula 11 (Formula Removed) Formula II oxidizing a compound of Formula II to give a compound of Formula III, (Formula Removed) methylaling a compound of Formula III to give a compound of Formula IV. (Formula Removed) reacting a compound of Formula IV with a compound of Formula V (Formula Removed) give a compound of Formula VI. (Formula Removed) deprotecting a compound of Formula VI to give a compound of Formula VII. (Formula Removed) and (i) reacting a compound of Formula VII with a compound of Formula VIII (Formula Removed) to give a compound of Formula IX, (Formula Removed) reacting a compound of Formula VII with a compound of Formula X (hal SO2 A') to give a compound of Formula XI. (Formula Removed) (iii) reacting a compound of Formula VII with a compound of Formula XII (A"COOF1) to give a compound of Formula XIII, (Formula Removed) (iv) reacting a compound of Formula VII with a compound of Formula XIV (hal- A'" ) to give a compound of Formula XV, (Formula Removed) wherein n is 1. 2 or 3, P1 is -C'(=O)OC'(CH:,)3. -C(=O)OC(CH3)2CHBr2 or -C(=O)OC(CH3)2CCl3, Rz is alkyl optionally substituted with halogen (for example, trifluoromethyl) or alkaryl ( for example, benzyl). Rzl is cycloalkylalkyi. alkaryl, cycloalkyl or alkyl optionally substituted with halogen; Y is oxygen or sulphur, A is -NRy or alkyl, A" is cycloalkyl, heterocyclyl or alkyl. hal is Br. Cl or 1. A'" is heterocyclylalkyl. cycloalkylalkyi, alkaryl or alkyl optionally substituted with - Rs and RN each independently is hydrogen, alkyl, C3-C6 alkenyl. C3-C6 alkynyl, carboxy, cycloalkyl. -S(O)mR5, aryl, alkaryl, heteroaryl, heterocyclyl, heteroarylalkyl. and heterocyclylalkyl, R5 is hydrogen, alkyl, alkenyl. alkynyl, aryl, cycloalkyl, alkaryl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl and in is an integer between 0-2. 7. A method for preparing compounds of Formulae XXIV, XXV, XXVI and XXVII, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers. diastereomers or N-oxides wherein the method comprises the steps of: a. reacting a compound of Formula XVII with a compound of Formula XVI to give a compound of Formula XVIII, (Formula Removed) b. reacting a compound of Formula XVIII with hydroxylamine hydrochloride to give a compound of Formula XIX, (Formula Removed) c. reacting a compound of Formula XIX with a compound of Formula XX (Formula Removed) to give a compound of Formula XXI, (Formula Removed) hydrolyzing a compound of Formula XXI to give a compound of Formula XXII. (Formula Removed) e reducing a compound of Formula XXII to give a compound of Formula XXIII, (Formula Removed) cyclizing a compound of Formula XXIII to give a compound of Formula XXIV, (Formula Removed) de-protecting a compound of Formula XXIV to give a compound of Formula XXV. (Formula Removed) reacting a compound of Formula XXV with a compound of Formula hal(CH2)-hal to give a compound of Formula XXVI. (Formula Removed) (ii) reacting a compound of Formula XXV with a compound of Formula (B' hal) to give a compound of Formula XXVII. (Formula Removed) wherein B' is alkaryl; B" is alkyl. hal is (Br. Cl or I) and v is an integer from 1-4, and P is alkyl or alkaryl. S. A method for preparing a compound of Formula XXX, its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers or N oxides wherein the method comprises the steps of: a. demethylaling a compound of Formula XXV11I to give a compound of Formula XXIX, (Formula Removed) b. reacting a compound of Formula XXIX with a compound of Formula C'-hal to give a compound of Formula XXX. (Formula Removed) wherein Rzl is cycloalkylalkyl, alkaryl. cycloalkyl or alkyl optionally substituted with halogen. C' is heterocyelylalkyl. cvcloalkylalkyl, cycloalkyl or C2-10 alkyl optionally substituted with halogen and hal is (Br, Cl or 1). A method for preparing compounds of Formulae XXXIII and XXXV. their pharmaceutically acceptable salts, pharmaceutically acceptable solvates. enantiomers. diastereomers or N-oxides wherein the method comprises the steps of: a. reacling a compound of Formula XXXI (Formula Removed) with a compound of Formula XXXII (Formula Removed) to give a compound of Formula XXXIII. (Formula Removed) reacting a compound of Formula XXX111 with a compound ot Formula XXXIV (Formula Removed) to give a compound of Formula XXXV, (Formula Removed) wherein Rz is alkyl optionally substituted with halogen or alkaryl, Rw is heteroarylalkyl, alkenyl or alkyl optionally substituted with cyano, carboxy or halogen. hal is Br. CM or 1, and 1) is cycloalkyl or hydrogen. A method lor preparing compounds of Formulae XXXVII. XXXVIII and XXXIX. their pharmaceutically acceptable salts, pharmaceutically acceptable solvates. enantiomers, diastereomers or N-oxides wherein the method comprises the steps of: a, reacting a compound of Formula XXXVI (Formula Removed) with a compound of Formula VIII (Formula Removed) to give a compound of Formula XXXVII. (Formula Removed) reacting a compound of Formula XXXVI (Formula Removed) with a compound of Formula XII (Formula Removed) to give a compound of Formula XXXVIII (Formula Removed) reacting a compound of Formula XXXVI (Formula Removed) with a compound of Formula X (Formula Removed) to give a compound of Formula XXXIX, (Formula Removed) wherein R, is alkyl optionally substituted with halogen or alkaryl. Rzl is cycloalkylalkyl. alkaryl. cycloalkyl or alkyl optionally substituted with halogen, Rx is hydrogen, alkyl, C3-C6 alkenyl, C3-C6 alkynyl, carboxy, cycloalkyl. -S(O)mR5, aryl, alkaryl, heteroaryl. heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, m is an integer between 0-2, R.s is hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, alkaryl. heteroaryl, heteroarylalkyl. heterocyclyl or heterocyclylalkyl, Y is oxygen or sulphur, A" is cycloalkyl. heierocyclyl or alkyl, and A is-NR,Rj or alkyl. II. A method for preparing compounds of Formulae XLIII, XLIV, XLV. XLVI. XLVII, XLVI1I. XLIX, L, LII. LIV and LIVa, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates. enantiomers, diastereomers or N-oxides wherein the method comprises the steps of: a. reacting a compound of Formula XL (Formula Removed) with a compound of Formula XL1 (Formula Removed) to give a compound of Formula XL11, (Formula Removed) hydroly/ing a compound of Formula XLII to give a compound of Formula XI,III. (Formula Removed) (ii) dehydrating a compound of Formula XLII to give a compound of Formula XLIV. (Formula Removed) (iii) oxidizing a compound of Formula XLII to give a compound of Formula XLV. (Formula Removed) reducing a compound of Formula XLV to give a compound of Formula XLVl. (Formula Removed) deprotecting a compound of Formula XLII to give a compound of Formula XLVII, (Formula Removed) (iv a) reacting a compound of Formula XLVII with a compound of Formula XII (Formula Removed) to give a compound of Formula XLVIII (Formula Removed) (iv b) reading a compound of Formula XLVIl with a compound of Formula X (Formula Removed) give a compound of Formula XLIX, (Formula Removed) (V) reducing a compound of Formula XLII to give a compound of Formula L (Formula Removed) (vi) reacting a compound of Formula XLII with a compound of Formula LI (Formula Removed) lo give a compound of Formula L1I. (Formula Removed) reacting a compound of Formula LII with a compound of Formula X (Formula Removed) to give a compound of Formula LIII, (Formula Removed) cyclizing a compound of Formula LIII to give a compound of Formula LIV, (Formula Removed) (vii) reacting a compound of Formula XLII with hydrazine hydrochloride to give a compound ol Formula LIVa, (Formula Removed) wherein RI, and R, together join to form a cycloalkyl or heterocyclyl ring optionally substituted with alkaryl or oxo, R, is hydrogen or -COOalkyl and RI, is hydrogen, RI, is hydrogen or -CH2OH, R1, is -(CH2)1-2OH, R, is hydrogen or -(CH2)1-2 OH and Rk is hydrogen. R, and R, together joins to form cycloalkyl or heterocyclyl ring, RI, and Rk are hydrogen. X1 and X2 are each independently hydrogen, alkyl, cycloalkyl, alkaryl, alkenyl. cycloalkylalkyl. heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, - (CH2)gC'(=O)NRxRy Or -(CH2)glC(=O)OR3 g is an integer from 0-3 and gi is an integer from 1-3, X1 and X2 together can optionally form a cyclic ring fused with the ring A of Formula 1, the ring containing 3-5 carbon atoms within the ring and having 2-3 heteroatoms selected from the group consisting of N, O and S. Rg is alkyl, cycloalkyl or heterocyclyl, Rx and Ry each independently is hydrogen, alkyl, C3-C6 alkenyl. C3-C6 alkynyl. carboxy. cycloalkyl. -S(O)mR5. aryl, alkaryl, heteroaryl, heterocyclyl, heteroarylalkyl. and heterocyclylalkyl, m is an integer between 0-2, and R5 is hydrogen, alkyl. alkenyl, alkynyl, aryl. cycloalkyl, alkaryl, heteroaryl. heteroarylalkyl, heterocyclyl or heterocyclylalkyl, A" is cycloalkyl, heterocyclyl or alkyl. A' is -NRXRy or alkyl and hal is (Br, Cl or 1). 1. A method for preparing compounds of Formulae FVII1. LIX and LX, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates. enantiomers, diaslereomcrs or N-oxides wherein the method comprises the steps of: a. reacting a compound of Formula FV (Formula Removed) with a compound of Formula LV1 (Formula Removed) to give a compound of Formula LVII. (Formula Removed) deprotecting a compound of Formula LVII to give a compound of Formula LVIII. (Formula Removed) ;i) reducing a compound of Formula LVIII to give a compound of Formula FIX, (Formula Removed) (ii) reacting a compound of Formula LVIII with a compound of Formula E'Mghal to give a compound of Formula LX (Formula Removed) wherein X| is hydrogen, alkyl. cycloalkyl, alkaryl, alkenyl, cycloalkylalkyl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl. -(CH2)gC(=O)NRNRy or- (CH2)glC(=0)OR., g is an integer from 0-3, gl is an integer from 1-3, Rg is alkyl, eyeloalkyl or heterocyclyl. Rx and Ry each independently is hydrogen, alkyl. C3-C6 alkenyl. C3-C6 alkynyl. carboxy. cycloalkyl. -S(O)mR5 aryl, alkaryl, heteroaryl. heterocyclyl, heteroarylalkyl, and heterocyclylalkyl, m is an integer between 0-2, Xg is hydrogen, alkyl, cycloalkyl, alkaryl, alkenyl, cycloalkylalkyl, heteroaryl, heterocyclyl, heteroarylalkyl. heterocyclylalkyl, E is alkyl. alkenyl or alkynyl. hal is Br. C'l or 1 13. A method for preparing a compound of Formula LXIII, its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers or N-oxides wherein the method comprises the steps of: a. reacting a compound of Formula LXI (Formula Removed) with a compound of Formula LXII (Formula Removed) to give a compound of Formula LX11I (Formula Removed) wherein Rz is alkyl optionally substituted with halogen or alkaryl. and c is an integer from 1 -3. 14. A method for preparing a compound of Formulae LXVI and LXVII their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers or N-oxides wherein the method comprises the steps of: a. reacting a compound of Formula LXIV (Formula Removed) with a compound of Formula LXV (Formula Removed) to give a compound of Formula LXVI, (Formula Removed) b deproteeting a compound of Formula LXV] to give a compound of Formula LXV1I, (Formula Removed) wherein Rz is alkyl optionally substituted with halogen or alkaryl, P2 is -O-tosyl. -O-mesyl, -O-4-bromophenylsulphonate, -O-4-nitrophenylsulfonale or-(')-inflate. (Formula Removed) hal is C'l. Br or 1, c is an integer from 1-3. n is 1.2 or 3, and PI is -C(=0)OC(CH3)3, -C(=O)OC (CH3)2CHBr2 or -C(=O)OC(CH3)2CC13. A method for preparing compounds of Formulae LXXIII and LXXIV, their pllarmaceutically acceptable salts, pharmaceutically acceptable solvates. enantiomers, diastereomers or N-oxides wherein the method comprises the steps of: a. reacting a compound of Formula LXVIII (Formula Removed) with hydroxyl amine hydrochloride to give a compound of Formula LXIX. (Formula Removed) reacting a compound of Formula LXIX with a compound of Formula XX (Formula Removed) to give a compound of Formula LXX, (Formula Removed) hydrolyzing a compound of Formula LXX to give a compound of Formula LXX1. (Formula Removed) reducing a compound of Formula LXXI to give a compound of Formula LXXII. (Formula Removed) cyclizing a compound of Formula LXXII to give a compound of Formula LXX11I, (Formula Removed) deprotecting a compound of Formula LXXIII to give a compound of Formula LXX1V, (Formula Removed) wherein P is alkyl or alkaryl, B' is alkaryl; and Rz is alkyl optionally substituted with halogen or alkaryl. 16. A method lor preparing a compound of Formula LXXX, its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers or N-oxides wherein the method comprises the steps of: a. reacting a compound of Formula LXXV (Formula Removed) with a compound of Formula LXXVI (Formula Removed) to give a compound of Formula LXXVI1. (Formula Removed) protecting a compound of Formula LXXVII with a compound of Formula P'-OH to give a compound of Formula LXXVI1I. (Formula Removed) c. reducing a compound of Formula LXXVIII to give a compound of Formula I. XXIX. (Formula Removed) cyclizing a compound of Formula LXXIX to give a compound of Formula LXXX. (Formula Removed) wherein X1 and X2 is hydrogen, alkyl, cycloalkyl, alkaryl. alkenyl, cycloalkylalkyl. heteroaryl. hclcrocyclyl. heteroarylalkyl. heterocyclylalkyl, -(CH2)gC(=O)NRxRy or - (CH2)glC(=O)OR.,. g is an integer from 0-3 . g1 is an integer from 1-3, X1 and X2 together can optionally form a cyclic ring fused with the ring A shown in Formula I, the ring containing 3-5 carbon atoms within the ring and having 2-3 heteroatoms selected from the group consisting of N. O and S, R is alkyl. cycloalkyl or heterocyclyl, Rx and Ry each independently is hydrogen, alkyl. C3-C6, alkenyl, C3-C6 alkynyl, carboxy. cycloalkyl, -S(O)mR5, aryl, alkaryl, heteroaryl, heterocyclyl, heteroarylalkyl, and helerocyclylalkyl. in is an integer between 0-2, R5 is hydrogen, alkyl, alkenyl. alkynyl, aryl, cycloalkyl, alkaryl, heteroaryl, heteroarylalkyl. helerocyclyl or helerocyclylalkyl, Q is a chiral resolving agent selected from L-Ephederine, D-Ephederine. Brucine. (1S. 2R) (-)-cis-l -amino-2-indanol, (1R 2S) (+)-eis-l-amino-2-indanol, (1R, 2R)-(-)-l,2-diamino cyclohcxane or (1S. 2S)-(+)-l,2-diamino cyclohexane or a-methylbenzylamine, and P' is alkyl. I 7. A method for preparing compounds of Formulae LXXX1V and LXXXV, their to give compounds of Formula LXXXI1 (Formula Removed) pharmaceiuically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diasiereomers or N-oxides wherein the method comprises the steps of: a. halogenating a compound of Formula LXXX1 and LXXX1II. (Formula Removed) reacting a compound of Formula LXXXIII with a compound of Formula F COONa to give a compound of Formula LXXXIV, (Formula Removed) hydrolyzing a compound of Formula LXXXIV to give a compound of Formula XXXV. (Formula Removed) wherein R, is alkyl optionally substituted with halogen or alkaryl, Rz1 is eycloalkylalkyl. alkaryl. cycloalkyl or alkyl optionally substituted with halogen), hal is Cl. Br or I. and E' is alkyl, alkenyl or alkynyl. 18. A method for preparing a compound of Formula LXXXVIII. its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers or N-oxides wherein the method comprises the steps of: (a) debenzylating a compound of Formula LXXXVI (Formula Removed) to give a compound of Formula LXXXVI1. (Formula Removed) (b) reacting a compound of Formula LXXXVI1 with a compound of Formula C'-hal to give a compound of Formula LXXXVI11. (Formula Removed) wherein Z3 is alkaryl, hal is Br, Cl or I, C' is heterocyclylalkyl. cycloalkylalkyl, cycloalkyl or C2-10 alkyl optionally substituted with halogen, R7 is alkyl optionally substituted with halogen or alkaryl.